Comprehensive Health Analysis Report

n1.care — Confidential
Generated
2026-06-04
55
male
172 cm
60 kg
55 Years, 4 Months

Executive Summary

Central Theme

PRSS1 hereditary chronic pancreatitis [d84] with progressive exocrine insufficiency [d59] drives malabsorption-related bone loss [d76] and gut dysbiosis [d67], while a concurrent cardiometabolic syndrome — hypertension [d79], prediabetes [d50], atherogenic dyslipidemia [cb2210], and hepatic steatosis [d14] — produces early coronary atherosclerosis [d74] despite a lean habitus. The glycemic phenotype requires formal adjudication between pancreatogenic (Type 3c) and primary Type 2 diabetes given the PRSS1 background, and a third axis of advanced polymicrobial periodontitis [d82][d83] compounds cardiovascular risk.

Situation
  • Prediabetes [d50] treatment-controlled; HbA1c 5.5% [b3487] on 4-agent regimen
  • Single FPG 7.2 mmol/L [b2799] discordant with same-date normals; Diabetes unconfirmed [d69]
  • Fecal elastase 85 µg/g [b5266] — severe EPI on PRSS1 background [d84]
  • Pancreatic cancer surveillance absent — 15 years overdue for PRSS1 carrier [w45]
  • aPTT persistently shortened 15.7–22.0 s [cb157]; Factor VIII 162.4% [b2782]
  • Femur neck T-score −1.8 [b4149]; Low bone turnover markers [cb2634][cb590]
  • Advanced periodontitis: A. actinomycetemcomitans 15,500 [b344] [d82]
  • Nocturnal systolic BP 128 mmHg [b6474] despite dual therapy [m5][m4]
  • LDL 1.1 mmol/L [b4042] well controlled on Atozet [m30][m51]
  • Copper metabolism abnormal: low ceruloplasmin [cb1025], elevated free copper % [cb1669]
Background
  • Hypertension [d79] since 2022; Dual therapy irbesartan [m5] + HCT [m4]
  • PRSS1 pathogenic variant [d84] identified Oct 2024; Creon [m17] started Nov 2025
  • 67 active medications/supplements; Extensive polypharmacy with mechanism-overlap clusters
  • CAC 19 [b1973] — mild atherosclerosis [d74]; Statin + ezetimibe since 2024
  • Hepatic steatosis [d14] and cholelithiasis 6.5 mm [d12] on dual ultrasound
  • Cervical MRI: C4-5/C5-6 disc prolapses abutting nerve roots [d62][d63]
  • Haemorrhoidectomy [p0] 2024; LASIK [p1] 1995
Assessment
  • T3cDM vs T2DM adjudication required before committing glycemic strategy long-term
  • Pancreatic cancer surveillance critically overdue for PRSS1 carrier at age 55
  • Coagulation panel uninterpretable while on nattokinase [m40] + lumbrokinase [m61]
  • Bergamot [m19] × atorvastatin CYP3A4 interaction poses statin-toxicity risk [w214]
  • Polypharmacy burden (67 items, ≥5 mechanism-overlap clusters) warrants deprescribing review
  • Low bone turnover precludes anti-resorptive therapy pending secondary-cause workup [w229]
  • Copper metabolism differential (Wilson vs zinc-induced) unresolved without urinary copper
Recommendation
  • Order OGTT with paired insulin/C-peptide + autoantibodies to adjudicate T3cDM vs T2DM
  • Order pancreatic MRI/MRCP — cancer surveillance critically overdue [w45]
  • Stop nattokinase [m40] + lumbrokinase [m61]; Refer hematology for coag interpretation
  • Stop bergamot [m19] + quercetin [m50] for documented drug interactions [w214][w220]
  • Order echocardiography to confirm/exclude LVH [d23]
  • Refer periodontist for AAP/EFP staging and treatment plan
  • Refer GI for SIBO treatment coordination with EPI management
  • Order 24-hr urinary copper + slit-lamp for copper workup [w187]
  • Order repeat DEXA + secondary osteoporosis workup [w226]
  • Deprescribing review: ~32 supplements to Review at Next Visit

Key Statistics

Identified Conditions 22
3 high priority, 4 moderate, 15 low/surveillance
Data Span 55
55 years, 4 months (1970-12-10 to 2026-04-07)
Total Diagnoses 86
58 chronic, 6 acute, 22 undetermined, 0 resolved
Total Procedures 2
Biomarker Groups 4,007
Total Biomarkers 7,563 1054
Most Recent Assessment
2026-04-07

Patient Snapshot

Identified Conditions

22 total
High Priority 3
1. Cardiometabolic Syndrome: Hypertension, Prediabetes with Insulin Resistance, and Atherogenic Dyslipidemia
2. Hereditary Chronic Pancreatitis with Progressive Exocrine Pancreatic Insufficiency
3. Advanced Periodontitis with Oral Dysbiosis
Moderate Priority 4
4. Gastrointestinal Dysbiosis and Methane-Positive SIBO
5. Hepatobiliary Disease: Steatosis, Cholelithiasis, and Gallbladder Polyps
6. Degenerative Musculoskeletal Disease with Osteopenia
7. Hypercoagulable Pattern: Shortened aPTT with Elevated Factor VIII and von Willebrand Factor
Low Priority / Surveillance 15
8. Probable Left Ventricular Wall Thickening on Non-Dedicated MRI
9. Copper Metabolism Abnormality
10. Persistently Elevated Rheumatoid Factor
11. Elevated Total IgE with Dust Mite Sensitization
12. Immunosenescent T-Cell Phenotype with CMV-Driven Expansion
13. Serologic Infectious Disease Exposures
14. Urological Findings: Trabeculated Bladder, Diverticulum, and Hydroceles
15. HPA Axis Findings: Variable Cortisol with Supplement Confounding
16. Abnormal Mitochondrial Functional Testing
17. NSUN2 Heterozygous Carrier Status
18. Nasal and Sinus Anatomical Variants
19. Incidental Structural Findings
20. Elevated Prostate Screening Markers with Positive Inguinal Lymph Node Pathology
21. Reduced Pulmonary Function on Spirometry
22. Mildly Elevated HVA/VMA Ratio

System Scores

Scores reflect current disease burden, trajectory, treatment effectiveness, and complication risk.

Multiple critical/concerning scores indicate need for urgent, coordinated multi-specialty care.
Gastrointestinal
38 /100
Key Concerns
  • Progressive EPI with fecal elastase 85 µg/g [b5266] on PRSS1 hereditary pancreatitis [d84]
  • Confirmed methane-positive SIBO peak methane 27 ppm [b5332] [d67]
  • Pancreatic cancer surveillance absent [w189]
Musculoskeletal
42 /100
Key Concerns
  • Advanced osteopenia femur neck T-score −1.8 [b4149] [d76]
  • Cervical disc prolapses abutting C5/C6 nerve roots [d62][d63]
  • Bilateral rotator cuff tears [d15][d66]
  • Persistently elevated RF [cb3223]
Otolaryngologic
45 /100
Key Concerns
  • Advanced periodontitis with A. actinomycetemcomitans [d82], T. forsythia [d81], T. denticola [d83]
  • Refractory Periodontitis reclassification recommended [d80]
  • Nasal anatomical variants [d46][d47]
Endocrine/Metabolic
52 /100
Key Concerns
  • Prediabetes with marked insulin resistance controlled on metformin [m21] [d50]
  • Multiple labels require reclassification [d73][d54][d70][d51]
  • Discordant FPG 7.2 mmol/L [b2799] unconfirmed [d69]
Cardiovascular
55 /100
Key Concerns
  • Hypertension with elevated nocturnal BP on irbesartan [m5] + HCT [m4] [d79]
  • Mild atherosclerosis CAC 19 [b1973] [d74]
  • LDL 1.1 mmol/L [b4042] controlled on atorvastatin [m30]
  • Probable LVH unconfirmed [d23]
Hematologic/Oncologic
55 /100
Key Concerns
  • Persistently shortened aPTT 15.7–22.0 s [cb157] with elevated Factor VIII 162.4% [b2782]
  • Intermittent D-Dimer elevation [cb1297]
  • Mildly elevated HVA/VMA ratio 1.5 [b3611] [cb1982]
  • Confounded by nattokinase [m40] + lumbrokinase [m61]
Pulmonology
60 /100
Key Concerns
  • No formal diagnoses — biomarker-driven
  • FEV1 3.07 L 67% predicted [b2914] preserved ratio PRISm pattern [w201]
  • Single timepoint
  • Confirmatory testing absent
Hepatobiliary
60 /100
Key Concerns
  • Hepatic steatosis [d14]
  • Cholelithiasis 6.5 mm [d12]
  • Low ceruloplasmin [cb1025] with elevated free copper % [cb1669] requiring workup
  • Normal transaminases
Immunologic/Allergic
65 /100
Key Concerns
  • Expanded CD8+CD28- immunosenescent T-cells 397 cells/µL [b1485]
  • Elevated IgE 154–404 kU/L [cb2066]
  • Reclassification of Chronic immune-suppression recommended [d57]
Urological/Renal
65 /100
Key Concerns
  • Trabeculated bladder wall [d39] and diverticulum [d43]
  • eGFR mildly reduced 70–86 mL/min KDIGO G2 [cb1575] [w204]
  • LUTS assessment absent
Infectious Disease
75 /100
Key Concerns
  • All serologic findings unconfirmed as active infections [d52][d55][d56][d58]
  • Confirmatory testing absent for all
Ophthalmologic
80 /100
Key Concerns
  • Mild Meibomian Gland Dysfunction [d53]
  • post-LASIK history [p1]
Neurological
85 /100
Key Concerns
  • NSUN2 heterozygous carrier status only [d85]
  • No clinical phenotype [w27]
Scoring Methodology
Critical: 0-29
  • Urgent issues requiring immediate attention
  • Life-threatening if untreated
Concerning: 30-49
  • Active issues requiring specialist management and close monitoring
Fair: 50-69
  • Some concerns requiring ongoing management
  • Moderate risk if unaddressed
Good: 70-89
  • Minor issues, well-managed
  • Low short-term risk
Optimal: 90-100
  • All markers normal or near-normal
  • Minimal concerns

Medical Timeline: The Evolution of Disease

55-Year Disease Progression
1970 Baseline and Early Structural Disease
2022 Emerging Cardiometabolic Disease
2024 Major Diagnostic Cascade
2025 Structural Mapping and Metabolic Escalation
2025 Pancreatic Decline and Immune/Infectious Workup
2025 Treatment Consolidation and Ongoing Surveillance
Show detailed journey
Critical
Progressing
Emerging
🚨 Critical/Urgent
⚠️ Warning
✅ Normal/Positive

1970-2015: Baseline and Early Structural Disease

Age 0-44 EMERGING
✅ LASIK surgery in Hong Kong [p1]
⚠️ Plantar fibroma identified on foot MRI [d5]
Clinical Significance

No systemic disease documented for the first four decades. Plantar fibromatosis is an isolated connective tissue finding without systemic implications.

Metabolic shift begins →

2022-2024 (Jan-Jun): Emerging Cardiometabolic Disease

Age 51-53 EMERGING
2022 Hypertension Diagnosis
APRIL Cardiac Screening
MAY Adrenal Screening
2022 — Hypertension Diagnosis
🚨 Hypertension diagnosed
• Started on irbesartan [m5] and hydrochlorothiazide [m4] [d79]
April — Cardiac Screening
⚠️ ECG automated report:
• "Excessive Overload of Left Atrium" [d1] — vendor-specific terminology
• Not standard nomenclature [w63]
May — Adrenal Screening
⚠️ Morning salivary cortisol 11.1 nmol/L [b2007] (ref 12–48) — below range
• Adrenal insufficiency label applied [d6] but unconfirmed without ACTH stimulation test
Clinical Significance

Hypertension is the first confirmed systemic disease, marking the onset of cardiometabolic risk. The ECG finding requires echocardiographic correlation.

Disease burden accelerates →

2024 (Jul-Dec): Major Diagnostic Cascade

Age 53-54 PROGRESSING
JULY Major Diagnostic Cascade
OCTOBER Genetic Findings
NOVEMBER Pancreatic/Prostate Screening
DECEMBER Oral Microbiome Testing
July — Major Diagnostic Cascade
🚨 Coronary artery calcium score 19 [b1973] — mild atherosclerotic coronary plaque deposits [d74]
• Started atorvastatin [m2] + ezetimibe [m6]
⚠️ HbA1c 6.1% [b3480] — prediabetes range per ADA [w75]
• Source labeled as "Diabetes" [d73]
• Started metformin [m21]
🚨 DEXA:
• Femur neck T-score −1.8 [b4149]
• Spine L1 T-score −1.4 [b6487] — osteopenia [d76]
⚠️ Abdominal ultrasound:
• Fatty liver with focal sparing [d14]
• Gallbladder polyps [d0][d13]
• 6.5 Mm gallstone [d12]
⚠️ Colonoscopy/gastroscopy:
• Left colon mild inflammation (colitis) [d9]
• Antral gastritis [d10]
⚠️ Haemorrhoidectomy [p0]
⚠️ Spirometry:
• FEV1 3.07 L [b2914] (ref ≥4.61) and FVC 3.83 L [b2917] (ref ≥5.25) — both below predicted
• Non-obstructive pattern
October — Genetic Findings
🚨 Genetic testing:
• PRSS1 pathogenic variant identified — hereditary chronic pancreatitis [d84]
• NSUN2 heterozygous carrier [d85]
November — Pancreatic/Prostate Screening
⚠️ Fecal elastase 209 µg/g [b5265] — borderline adequate (ref ≥200)
⚠️ Prostate Health Index (PHI) [cb3100] 106.11 [b5659] — elevated prostate screening marker (PSA normal at 0.81 [b5663])
December — Oral Microbiome Testing
⚠️ Oral microbiome testing:
• Elevated Parvimonas micra [d3]
• Low Lactobacilli [d2]
• Low S. salivarius [d4]
Clinical Significance

A single diagnostic window reveals five major disease axes simultaneously — cardiometabolic disease, hereditary pancreatitis, hepatobiliary pathology, osteopenia, and oral dysbiosis. The PRSS1 variant is the most consequential finding, carrying lifetime pancreatic cancer risk requiring annual surveillance [w45].

Structural mapping begins →

2025 (Jan-Jun): Structural Mapping and Metabolic Escalation

Age 54 PROGRESSING
MARCH Prediabetes Confirmation
APRIL Full-Body MRI
MAY Biological Age Markers
March — Prediabetes Confirmation
⚠️ HbA1c 5.7% (39 mmol/mol) [b3468] — confirmed prediabetes [d50]
• Lobeglitazone [m27] added
April — Full-Body MRI
🚨 Full-body MRI:
• 30+ Structural findings including probable LV wall thickening 14 mm [d23]
• Bilateral shoulder pathology (infraspinatus partial tear [d15], supraspinatus partial tear [d21])
• Cervical disc bulges [d35]
• Knee chondromalacia grade 4 [d18]
• Bladder wall trabeculation [d39]
• Bladder diverticulum [d43]
May — Biological Age Markers
⚠️ Mitochondrial functional testing:
• Reduced efficiency score 46th percentile [b4652] (ref 90–100)
• Elevated citrate synthase [b1851] [d51]
⚠️ Multiple biological age markers elevated above chronological age (55):
• Epigenetic age 57.9 [b2604]
• Immune biological age 59.0 [b3718]
• Hormone system age 61.8 [b3630]
Clinical Significance

The full-body MRI reveals extensive degenerative musculoskeletal disease including cervical disc pathology abutting nerve roots. The probable LVH finding on non-dedicated MRI requires dedicated cardiac imaging for confirmation [w61].

Pancreatic function declines →

2025 (Jul-Nov): Pancreatic Decline and Immune/Infectious Workup

Age 54-55 PROGRESSING
JULY Immune/Hormone Workup
SEPTEMBER BP/Coagulation Monitoring
NOVEMBER Severe EPI Diagnosis
July — Immune/Hormone Workup
⚠️ Serologic panels:
• Schistosoma IgG positive [d58]
• Coxsackievirus A7/B1 IgA+IgG positive [d55] — exposure evidence
• Not confirmed active infections
⚠️ DUTCH urinary hormone panel: variable cortisol ratios [d70] — subsequent panel normalized
⚠️ IgE 404 kU/L [b3737] (ref ≤100) — elevated without specific allergic disease
September — BP/Coagulation Monitoring
⚠️ Ambulatory BP monitoring:
• Nocturnal systolic 128 mmHg [b6474] (ref 105–120)
• Nocturnal diastolic 82 mmHg [b2371] (ref 65–70) — elevated despite treatment
⚠️ Coagulation:
• Factor VIII 162.4% [b2782] (ref 50–150)
• vWF 189.6% [b7390] (ref 50–150)
• aPTT persistently shortened [cb157]
November — Severe EPI Diagnosis
🚨 Fecal elastase drops to 85 µg/g [b5266] (ref ≥200) — severe EPI [d59]
• Pancrelipase (Creon) [m17] started
🚨 Cervical MRI:
• Cervical spondylosis [d61] with C4-5 disc prolapse abutting right C5 nerve root [d62]
• C5-6 prolapse abutting right C6 nerve root [d63]
⚠️ Positive Microscopic Observation of Inguinal Lymph Node Block [cb2500] [b4625] and Prostate Suspicion Criteria Met 5.0 [b5666] (ref 0–4) — same-date findings
• eGFR 70.0 mL/min [b2708]
Clinical Significance

Pancreatic function deteriorates from borderline to severe insufficiency within 12 months, consistent with PRSS1-driven progressive fibrosis [w173]. Cervical disc prolapses with nerve root abutment represent the most actionable musculoskeletal finding.

Treatment consolidation begins →

2025 (Dec)-2026 (Apr): Treatment Consolidation and Ongoing Surveillance

Age 55 EMERGING
January — SIBO and Renal Surveillance
⚠️ Breath test: peak methane 27 ppm [b5332] (ref ≤10) — methane-positive SIBO confirmed [d67]
⚠️ Fasting glucose 7.2 mmol/L [b2799] (ref 3.9–6.0) on one measurement, but same-date values 5.1 [b2802] and 6.3 mmol/L [b3163] — discordant [d69]
• Requires confirmatory repeat [w77]
⚠️ Periodontal pathogens confirmed:
• Tannerella forsythia [d81]
• Aggregatibacter actinomycetemcomitans 15,500 [b344] (ref <10,000) [d82]
• Treponema denticola [d83]
⚠️ eGFR [cb1573] 86.0 mL/min [b2709] (ref ≥90) — mildly reduced
April — Treatment Control
✅ HbA1c 5.5% (37 mmol/mol) [b3487] — treatment-controlled on metformin [m21] + lobeglitazone [m27]
✅ LDL cholesterol 1.1 mmol/L [b4042] — well controlled on atorvastatin [m30] + ezetimibe [m51]
⚠️ eGFR (CKD-EPI) [cb1575] 84.0 mL/min [b721] (ref ≥90) — persistently mildly reduced (KDIGO G2)
⚠️ Ferritin trending low: 27.4 µg/L [b2841] (ref 22–322) despite iron supplementation [m41]
Clinical Significance

Glycemic control is maintained in the prediabetes range on treatment, with LDL well controlled. However, a single unconfirmed FPG of 7.2 mmol/L raises the possibility of diabetes progression requiring confirmatory testing. SIBO diagnosis mechanistically links to the established EPI. Mildly reduced eGFR (70–86 mL/min) across three measurements warrants renal surveillance.

Identified Conditions

22 Total
#1

Cardiometabolic Syndrome: Hypertension, Prediabetes with Insulin Resistance, and Atherogenic Dyslipidemia

High
Active partially controlled
Related Diagnoses

Hypertension [d79]

Prediabetes [d50]

Mild atherosclerotic coronary plaque deposits [d74]

Fatty liver with focal fatty sparing [d14]

Mild hyperlipidemia [d71] (reframed as atherogenic dyslipidemia with small dense LDL phenotype)

Diabetes [d73] (source-record-only: HbA1c 6.1% is prediabetes per ADA, not diabetes [w75])

Impaired fasting glucose [d68] (source-record-only: discordant same-date values)

Diabetes Mellitus [d69] (objective abnormality, intermittent/discordant: single unconfirmed FPG 7.2 mmol/L)

Key Evidence

HbA1c trend [cb1925]: 6.1% [b3480] (Jul 2024) → 5.7% [b3468] (Mar 2025) → 5.9% [b3476] (Nov 2025) → 5.5% [b3487] (Apr 2026) — treatment-controlled in prediabetes range on metformin [m21] + lobeglitazone [m27]

Fasting insulin [cb2099] repeatedly elevated: 28.0 [b3823], 30.2 [b3825], 28.3 uiu/ml [b3828] (ref 3.0–25.0) — indicating insulin resistance

Proinsulin [cb3086] 76.0 pmol/L [b5629] (ref 3.6–22.0) — markedly elevated, consistent with beta-cell stress

C-Peptide [cb837] elevated: 2.55 nmol/L [b1429] (ref 0.27–1.28) — indicating hyperinsulinemic state, not beta-cell failure

CAC score [cb1160] 19 [b1973] — mild but non-zero atherosclerotic burden

LDL Phenotype Pattern [cb2210] Type B (abnormal) [b4052][b4053] with LDL-3 0.26 mmol/L [b4059] (ref 0–0.2) and LDL-4 0.08 mmol/L [b4061] (ref 0–0.01) — small dense LDL predominance

Triglycerides [cb3743] intermittently elevated: 2.9 [b6918], 2.4 [b6927] mmol/L (ref ≤1.7)

LDL [cb2205] 1.1 mmol/L [b4042] — well controlled on atorvastatin [m30] + ezetimibe [m51]

Nocturnal systolic BP 128 mmHg [b6474] (ref 105–120), nocturnal diastolic 82 mmHg [b2371] (ref 65–70) — incompletely controlled on irbesartan [m5] + hydrochlorothiazide [m4]

Hepatic steatosis on ultrasound [d14] — mechanistically linked to insulin resistance

Clinical Significance

This patient has a confirmed cardiometabolic syndrome with four interlinked components: (1) hypertension with incomplete nocturnal control despite dual-agent therapy [m5][m4]; (2) prediabetes with marked insulin resistance (fasting insulin up to 30 uiu/ml, proinsulin 76 pmol/L), currently treatment-controlled to HbA1c 5.5% by metformin [m21] + lobeglitazone [m27] + chromium [m10] + alpha lipoic acid [m12]; (3) atherogenic dyslipidemia with Type B LDL phenotype and elevated small dense LDL subfractions, controlled to LDL 1.1 mmol/L by atorvastatin [m30] + ezetimibe [m51]; and (4) hepatic steatosis, the liver manifestation of insulin resistance. The single FPG of 7.2 mmol/L [b2799] on 2026-01-10 is in the diabetes range [w75] but is discordant with same-date values of 5.1 [b2802] and 6.3 mmol/L [b3163], and the most recent HbA1c of 5.5% does not confirm diabetes; ADA guidelines require confirmatory repeat of the above-threshold test [w77]. The elevated C-Peptide and proinsulin argue against Type 3c diabetes (which shows beta-cell failure) and for a Type 2 insulin-resistant phenotype [w194]. The patient's lean habitus (BMI 20.3) is atypical for metabolic syndrome and raises the question of whether pancreatic disease contributes to metabolic dysregulation independently. CAC 19 indicates existing subclinical atherosclerosis warranting ongoing surveillance.

Workup
  • order OGTT (75 g) with paired insulin and C-peptide at 0, 30, 60, and 120 min + diabetes autoantibodies (GAD65, IA-2, ZnT8) + pancreatic polypeptide response to adjudicate Type 3c pancreatogenic diabetes vs primary T2DM [w194][w230].
    • This patient's PRSS1 hereditary pancreatitis [d84] could produce T3cDM via beta-cell destruction
    • Formal differentiation is required before committing to the current TZD/metformin strategy.
    • Hold metformin [m21] ≥48 h, lobeglitazone [m27] ≥7 d, chromium [m10] ≥24 h, and alpha lipoic acid [m12] ≥24 h pre-test to eliminate glucose-lowering confounding [w230].
    • "Diabetes" [d73] is a source-record-only label
    • HbA1c 6.1% [b3480] is prediabetes per ADA, not diabetes (threshold ≥6.5%) [w1]
    • "Impaired fasting glucose" [d68] reflects discordant same-date glucose values (7.2 [b2799], 6.3 [b3163], 5.1 mmol/L [b2802])
    • Glycemic category unconfirmed pending OGTT.
  • order Repeat fasting plasma glucose to confirm or exclude the single FPG 7.2 mmol/L [b2799] that reached the ADA diabetes threshold (≥7.0 mmol/L) [w77][w79]
    • Diabetes Mellitus [d69] is an objective abnormality, intermittent/discordant
    • Most FPG values are normal (4.3–5.2 mmol/L [cb1612]) and HbA1c has never reached ≥6.5%.
    • Result will reflect treatment-controlled state on metformin [m21] + lobeglitazone [m27] + chromium [m10] + ALA [m12]
    • A repeat FPG ≥7.0 on current regimen would carry higher clinical weight than the original discordant single value.
    • If FPG confirms ≥7.0 on treatment, the OGTT (ordered separately) will adjudicate the glycemic category.
Treatment
  • continue Metformin 500 mg twice daily [m21]
    • HbA1c 5.5% [b3487] treatment-controlled [cb1925]
  • continue Lobeglitazone 0.25 mg daily [m27]
  • continue Atorvastatin 20 mg + ezetimibe 10 mg (Atozet) [m30][m51]
    • LDL 1.1 mmol/L [b4042] [cb2205]
  • continue Irbesartan 150 mg (Aprovel) [m5] + hydrochlorothiazide 25 mg [m4]
  • stop Bergamot orange 500 mg [m19] (with prescriber agreement)
    • Bergamot contains furanocoumarins (bergamottin) that irreversibly inhibit CYP3A4
    • Atorvastatin is a CYP3A4 substrate, with preclinical data showing up to 3-fold AUC increase [w214] and class guidance recommends avoiding strong CYP3A4 inhibitors with atorvastatin
  • stop Quercetin phytosome 250 mg [m50] (with prescriber agreement)
    • Quercetin inhibits CYP3A4 and OATP1B1, the primary metabolic pathways for lobeglitazone, likely increasing TZD exposure and fluid-retention risk [w220]
Conditional Follow-up
  • if Repeat FPG confirms ≥7.0 mmol/L → Reclassify glycemic status
    • OGTT results determine whether T3cDM (low C-peptide, blunted PP response) or T2DM (elevated C-peptide, preserved PP)
    • Drug-class selection is endocrinology-directed [w194]
  • if Repeat FPG <7.0 mmol/L and OGTT <11.1 mmol/L at 2 h → Prediabetes confirmed
    • Continue current regimen
  • if Nocturnal BP remains elevated on repeat ambulatory monitoring → Modify (prescriber/cardiology-directed) antihypertensive regimen, considering evening chronotherapy or addition of a third agent
Monitoring & Cautions
  • watch Cumulative glucose-lowering load (metformin [m21] + lobeglitazone [m27] + chromium [m10] + alpha lipoic acid [m12])
    • Single FPG 3.0 mmol/L [b2792] raises hypoglycemia concern on the combined regimen
  • watch Nocturnal BP control
    • Nocturnal systolic 128 mmHg [b6474] (ref 105–120) and diastolic 82 mmHg [b2371] (ref 65–70) despite dual therapy [m5][m4]
  • watch Hydrochlorothiazide [m4] × glucose
    • Thiazides impair β-cell insulin secretion
    • Monitor HbA1c [cb1925] and fasting glucose [cb1612] at each visit given prediabetes [d50] and cumulative glucose-lowering regimen
  • watch eGFR [cb1575]
    • Irbesartan [m5] + hydrochlorothiazide [m4] may contribute to the persistently mildly reduced eGFR 84–87 mL/min [b2711][b2721]
    • Check creatinine and eGFR annually
    • Avoid NSAIDs
  • watch Triglycerides [cb3743]
    • Intermittently elevated (peak 2.9 mmol/L [b6918], ref ≤1.7)
    • Most recent normalized to 1.0 [b6934]
Clinical Rationale

OGTT with paired insulin/C-peptide and PP response is selected over plain repeat FPG because this patient's PRSS1 hereditary pancreatitis [d84] opens a pancreatogenic diabetes pathway requiring fundamentally different long-term management [w194]. T3cDM shows low C-peptide and blunted PP response (median fold-change 1.81 vs 3.28 in T2DM [w211]), whereas this patient's elevated C-Peptide 2.55 nmol/L [b1429] and proinsulin 76.0 pmol/L [b5629] currently suggest a T2DM phenotype [w194] — but formal adjudication is needed. Bergamot is stopped rather than atorvastatin switched because the Atozet combination is effective and convenient; if bergamot retention is preferred, switching to rosuvastatin (not CYP3A4-metabolized) is the pharmacokinetically rational alternative [w214]. Quercetin removal is supported by lobeglitazone's reliance on CYP3A4 and OATP1B1 for metabolism — pathways quercetin inhibits — with ketoconazole (a strong CYP3A4 inhibitor) increasing lobeglitazone AUC by ~33% [w220].

#2

Hereditary Chronic Pancreatitis with Progressive Exocrine Pancreatic Insufficiency

High
Active worsening
Related Diagnoses

Hereditary chronic pancreatitis [d84]

pancreatic insufficiency [d59]

Key Evidence

PRSS1 pathogenic variant identified on genetic testing [d84] — autosomal dominant hereditary pancreatitis with ~80% penetrance [w43]

Fecal elastase [cb2883]: 209 µg/g [b5265] (Nov 2024, borderline adequate) → 85 µg/g [b5266] (Nov 2025, severe EPI <100 µg/g [w152]) → "Normal" [b5267] (Dec 2025, possibly confounded by Creon supplementation [m17])

Fat-Free Mass Index [cb1619] 16.7 kg/m² [b2814] (ref ≥17.0) — consistent with malabsorption

N-MID Osteocalcin [cb2634] 11.0 µg/L [b4840] (ref 24–46) — suppressed bone formation marker

Clinical Significance

This patient carries a pathogenic PRSS1 variant, which is causative for autosomal dominant hereditary pancreatitis (not merely a risk factor) [w192]. The functional consequence is now manifest: fecal elastase declined from borderline (209 µg/g) to the severe EPI range (85 µg/g) within 12 months, requiring enzyme replacement with pancrelipase (Creon) [m17]. No documented episodes of acute pancreatitis appear in the record, and no pancreatic imaging (MRCP/EUS) has been performed to assess morphologic changes. Critically, PRSS1 carriers face a 50- to 87-fold increased risk of pancreatic adenocarcinoma, with annual MRI/MRCP and/or EUS surveillance recommended from age 40 per AGA/ASGE guidelines [w45][w47] — the patient is 55 and this surveillance is absent from the record. The low fat-free mass index and low osteocalcin suggest ongoing nutritional consequences of malabsorption that connect to the osteopenia cluster. A confirmatory repeat of fecal elastase on formed stool off enzyme supplementation would clarify native pancreatic function. Additionally, elevated urinary oxalate (Oxalic Acid/Creatinine Ratio [cb2858] 119.29 mmol/molcr [b5205] on Jan 2026, ref 0–78, and 173.0 [b5203] on Jul 2025, ref 8.9–67) is a recognized downstream complication of EPI-related fat malabsorption: unabsorbed fatty acids saponify luminal calcium, leaving oxalate unbound for colonic absorption (enteric hyperoxaluria), increasing nephrolithiasis risk.

Workup
  • order (GI-coordinated) pancreatic MRI/MRCP or EUS for cancer surveillance
    • Critically overdue
    • PRSS1 carriers face a 50- to 87-fold increased risk of pancreatic adenocarcinoma (cumulative ~50% by age 75), with annual alternating MRI/MRCP and EUS recommended from age 40 per AGA/ASGE guidelines [w45][w47][w189].
    • Patient is 55 with no pancreatic imaging on record.
  • order Repeat fecal elastase [cb2883] on formed stool off pancrelipase [m17] ≥72 h to assess native pancreatic function.
    • Third value "Normal" [b5267] is uninterpretable while on enzyme replacement
    • The decline from 209 µg/g [b5265] (borderline) to 85 µg/g [b5266] (severe EPI, <100 µg/g [w152]) within 12 months needs confirmation of persistence [w192].
  • order Fat-soluble vitamin panel: 25-hydroxyvitamin D, vitamin K functional markers (PIVKA-II/DCP, INR), serum calcium, magnesium, prealbumin
    • EPI-driven malabsorption surveillance.
    • Note: results interpreted in the context of active cholecalciferol 40 mcg [m56] and vitamin K2 120 mcg [m36] supplementation
    • Values reflect treated status
    • A low 25(OH)D on supplementation would indicate malabsorption rather than inadequate intake.
    • Vitamin K deficiency independently predicts osteoporosis in males with chronic pancreatitis (OR 4.23) [w195][w173].
Treatment
  • continue Pancrelipase (Creon) 30,000 units with meals [m17] (10,000 units × 3 per meal)
  • continue Iron 28 mg every other day [m41]
    • Ferritin [cb1632] declining (nadir 17.7 µg/L [b2830], ref 22–322) despite supplementation, consistent with EPI-related malabsorption
Conditional Follow-up
  • if Native fecal elastase confirms severe EPI off enzymes → Titrate Creon dose upward guided by steatorrhea symptoms and 72-hour fecal fat test
  • if Vitamin K functional markers abnormal (elevated DCP, low INR) → Increase vitamin K2 [m36] dose and reassess
Monitoring & Cautions
  • watch Enteric hyperoxaluria
    • Urinary oxalate elevated (173.0 [b5203], 119.29 mmol/molcr [b5205], ref 0–78) [cb2858]
    • EPI-related fat malabsorption leaves oxalate unbound for colonic absorption, increasing nephrolithiasis risk
  • watch Declining ferritin trajectory [cb1632] despite iron supplementation
    • If ferritin continues to fall, investigate for concurrent blood loss or switch to intravenous iron
Clinical Rationale

Pancreatic cancer surveillance is the highest-priority gap in this patient's care. PRSS1 carriers have a cumulative cancer risk of ~50% by age 75, and at 55, this patient has no pancreatic imaging record [w189]. MRCP is preferred over CT to avoid cumulative radiation in a surveillance setting requiring annual imaging [w47]. The fecal elastase recheck off enzymes is necessary because Creon [m17] supplementation may contribute exogenous elastase to stool, confounding the result [cb2883].

#3

Advanced Periodontitis with Oral Dysbiosis

High
Active worsening
Related Diagnoses

Refractory Periodontitis [d80] (reframed: "Refractory Periodontitis" is not in the current 2017/2018 AAP/EFP classification [w72]; the correct framework is Periodontitis with staging and grading [w73], likely Grade C given treatment resistance [w74])

Tannerella forsythia [d81]

Aggregatibacter actinomycetemcomitans in the oral cavity [d82]

Advanced periodontitis due to Treponema denticola [d83]

Low Lactobacilli Species [d2]

Elevated Parvmonas Micra [d3]

Low Streptococcus Salivarius [d4]

Elevated Campylobacter Rectus [d7]

Key Evidence

Aggregatibacter actinomycetemcomitans [cb192] 15,500 [b344] (ref <10,000) [d82]

Parvimonas micra [cb2905] 7,130,000 cfu/ml [b5303] (ref ≤4,000,000) [d3]

Fusobacterium nucleatum [cb1698] above reference lines [b3032]

Campylobacter rectus [cb903] 1,830,000 cfu/ml [b1566] (ref ≤1,000,000) [d7]

Enterococcus faecalis (Saliva) [cb1512] 13,360 cfu/ml [b2535] (ref ≤1,000)

Pseudomonas aeruginosa (Saliva) [cb3125] 62,720,000 cfu/ml [b5699] (ref ≤1,000,000)

Lactobacillus species (Saliva) [cb2234] below detection limit [b4110]

Streptococcus salivarius (Saliva) [cb3462] below detection limit [b6324]

Clinical Significance

The oral cavity harbors a high-burden polymicrobial infection with three "red complex" periodontal pathogens (T. forsythia, T. denticola, A. actinomycetemcomitans) alongside overgrowth of opportunistic organisms (P. aeruginosa, E. faecalis) and depletion of protective commensals (Lactobacillus, S. salivarius). This represents advanced, likely Grade C periodontitis per current AAP/EFP classification [w73]. Advanced periodontitis is an independent risk factor for atherosclerotic cardiovascular disease through systemic cytokine release, direct bacteremia, and molecular mimicry [w193]. In this patient with confirmed coronary atherosclerosis [d74], periodontal disease is a modifiable contributor to cardiovascular risk.

Workup
  • refer Periodontist to (1) restage disease using the current 2017/2018 AAP/EFP staging/grading framework
    • "Refractory Periodontitis" [d80] is not current terminology [w72]
    • The pattern (red complex pathogens, treatment resistance) fits Periodontitis, likely Grade C [w74], (2) determine whether adjunctive systemic antibiotics are indicated for Aggregatibacter actinomycetemcomitans [d82] (15,500 [b344], ref <10,000), and (3) establish a comprehensive treatment plan addressing Tannerella forsythia [d81] and Treponema denticola [d83]
Monitoring & Cautions
  • watch Cardiovascular risk
    • Advanced periodontitis is an independent ASCVD risk factor through bacteremia and systemic inflammation [w193]
    • This patient has confirmed coronary atherosclerosis (CAC 19 [b1973]) [d74] and periodontal disease is a modifiable contributor
Clinical Rationale

Antibiotic selection for Aa-positive periodontitis (typically amoxicillin + metronidazole) is specialist-directed because regimen, duration, and approach depend on staging, probing depths, and initial debridement response — not primary-care authorship [w73][w74]. The systemic cardiovascular link is documented by the 2020 EFP/WHF Consensus Report [w193].

The Biological Story

Central Pathophysiology

This patient's biology is shaped by the convergence of two independent and confirmed disease axes. The first is a cardiometabolic syndrome — confirmed hypertension, prediabetes with marked insulin resistance, and atherogenic dyslipidemia with small dense LDL predominance — which has produced hepatic steatosis and early coronary atherosclerosis despite a lean habitus. The second axis is PRSS1-related hereditary chronic pancreatitis now manifesting as progressive exocrine pancreatic insufficiency, with functional deterioration from borderline to severe enzyme deficiency within twelve months. A third confirmed axis of advanced polymicrobial periodontitis adds a chronic inflammatory source with established cardiovascular implications.

Condition Relationships

Root
Critical
Warning
Neutral
Protective
Drives / Worsens
Allows / Impairs
Reduces / Protects
Associates / Linked
Drag to pan Scroll to zoom Hover for details

Additional Risk Pathways

Chronic Cmv Infection
Drives
Immunosenescent T-Cell Expansion
Cross-Condition Interactions 11
View details
Condition A Affects Condition B Mechanism
Insulin Resistance Drives Hepatic Steatosis
  • Hyperinsulinemia overstimulates hepatic de novo lipogenesis, converting excess carbohydrates into triglycerides that accumulate as hepatic steatosis [w180]
  • Patient waypoints: fasting insulin repeatedly elevated (28.0 [b3823], 30.2 [b3825] uiu/ml, ref 3–25) [cb2099], proinsulin 76.0 pmol/L [b5629] (ref 3.6–22) [cb3086], hepatic steatosis confirmed on dual ultrasound [d14][d77]
Hepatic Steatosis Drives Atherogenic Dyslipidemia
  • Steatotic liver exports triglyceride-rich VLDL1
  • CETP exchanges triglycerides into LDL particles, which hepatic lipase hydrolyzes into small dense LDL [w179]
  • Patient waypoints: LDL Type B pattern [b4052][b4053] [cb2210], LDL-3 elevated 0.26 mmol/L [b4059] (ref 0–0.2) [cb2213], LDL-4 elevated 0.08 mmol/L [b4061] (ref 0–0.01) [cb2214], VLDL elevated 0.7 mmol/L [b7264] (ref 0.1–0.6) [cb3837]
  • Treatment-controlled by atorvastatin [m30] + ezetimibe [m51]
Atherogenic Dyslipidemia Drives Coronary Atherosclerosis
  • Small dense LDL penetrates arterial endothelium, binds subendothelial proteoglycans, undergoes oxidation, and initiates plaque formation [w179]
  • Patient waypoints: LDL Type B [cb2210] [b4052], CAC score 19 [b1973] [cb1160], on statin therapy [m30]
Hypertension Worsens Coronary Atherosclerosis
  • Elevated blood pressure accelerates endothelial damage and plaque progression
  • Patient waypoints: nocturnal systolic 128 mmHg [b6474] (ref 105–120) [cb3530], nocturnal diastolic 82 mmHg [b2371] (ref 65–70) [cb1395] despite irbesartan [m5] + hydrochlorothiazide [m4], CAC 19 [b1973] [cb1160]
Prss1 Hereditary Pancreatitis Drives Exocrine Pancreatic Insufficiency
  • Gain-of-function PRSS1 mutations cause premature intrapancreatic trypsinogen activation, leading to chronic inflammation, fibrosis, and progressive acinar cell loss [w192]
  • Patient waypoints: pathogenic PRSS1 variant identified [d84], fecal elastase decline from 209 [b5265] to 85 µg/g [b5266] [cb2883], on enzyme replacement [m17]
Exocrine Pancreatic Insufficiency Drives Methane-Positive Sibo
  • Loss of pancreatic proteases eliminates antimicrobial defense
  • Undigested macronutrients trigger the ileal brake (PYY/GLP-1 mediated), slowing transit and creating conditions for bacterial/methanogen overgrowth [w172]
  • Patient waypoints: fecal elastase 85 µg/g [b5266] [cb2883], peak methane 27 ppm [b5332] [cb2921]
  • Methane further slows transit by up to 59% [w190]
Exocrine Pancreatic Insufficiency Drives Osteopenia
  • EPI causes fat-soluble vitamin malabsorption (vitamins D and K), leading to impaired bone mineralization [w173]
  • Vitamin K deficiency independently predicts osteoporosis in males (OR 4.23) [w195]
  • Patient waypoints: fecal elastase 85 µg/g [b5266] [cb2883], femur neck T-score −1.8 [b4149] [cb2264], N-MID Osteocalcin 11.0 µg/L [b4840] (ref 24–46) [cb2634] indicating suppressed bone formation
  • Partially mitigated by cholecalciferol [m56] + vitamin K2 [m36]
Advanced Periodontitis Associates with Coronary Atherosclerosis
  • Periodontal pathogens release systemic pro-inflammatory cytokines and cause transient bacteremia
  • Live pathogens have been isolated from human atherosclerotic plaques [w193]
  • Patient waypoints: confirmed high-burden periodontal infection (Aa 15,500 [b344] [cb192], F. nucleatum above reference [b3032] [cb1698]) and confirmed CAC 19 [b1973] [cb1160], but direct inflammatory mediator chain (CRP, IL-6) not consistently elevated in this patient — association rather than demonstrated causation
Chronic Cmv Infection Drives Immunosenescent T-Cell Expansion
  • Persistent CMV antigen stimulation causes clonal expansion and "memory inflation" of CMV-specific CD8+ T-cells that lose CD28 costimulatory molecules, narrowing the naïve T-cell repertoire [w181]
  • Patient waypoints: CMV latent EliSpot SI 160.0 [b2191] [cb1294], CMV IgG 3.686 [b2187] [cb1290], CD8+CD28- cells 397 cells/ul [b1485] (ref 17–364) [cb865], CD4/CD8 ratio low at 0.86 [b1468] [cb858]
Insulin Resistance Associates with Possible Progression Toward Diabetes
  • A single FPG of 7.2 mmol/L [b2799] reached the diabetic threshold [w75], but same-date values were discordant (5.1 [b2802], 6.3 mmol/L [b3163]) and HbA1c has not reached ≥6.5% [w149]
  • The elevated C-Peptide (2.55 nmol/L [b1429], ref 0.27–1.28) [cb837] argues for Type 2 insulin-resistant mechanism rather than Type 3c pancreatic beta-cell failure [w194]
  • Confirmation requires repeat FPG [w77] and OGTT
Hypertension Associates with Probable Lv Wall Thickening
  • Chronic pressure overload from hypertension drives compensatory LVH
  • Patient has confirmed hypertension [d79] and 14 mm wall thickness reported on MRI [d23], but measurement is from non-dedicated MRI lacking ECG gating [w61] — dedicated CMR or echocardiography required for confirmation

Detailed Findings by System

Gastrointestinal

38 CONCERNING

Diagnoses

Diagnosis Date Status Citation
Hereditary chronic pancreatitis 2024-10-17 Chronic [d84]
pancreatic insufficiency 2025-11-18 Chronic [d59]
Methane-Positive Small Intestinal Bacterial Overgrowth (SIBO) 2026-01-02 Active [d67]
COLITIS 2024-07-19 Acute [d9]
ACUTE GASTRITIS 2024-07-19 Acute [d10]
Small umbilical hernia containing fat 2025-04-05 Chronic [d44]
Low Lactobacilli Species 2024-12-01 Active [d2]
Elevated Parvmonas Micra 2024-12-01 Active [d3]
Low Streptococcus Salivarius 2024-12-01 Active [d4]
Elevated Campylobacter Rectus 2024-12-01 Active [d7]

Key Biomarkers

Marker Date Value Reference Status Citation
Peak Methane (Breath) 2026-01-02 27.0 ppm ≤ 10.0 Elevated [b5332]
Peak Methane (Exhaled Gas) 2025-11-17 16.0 ppm ≤ 10.0 Elevated [b5333]
Bifidobacterium bifidum (Stool) 2024-11-20 Low — Low [b1093]
Lactose Degraders (Stool) 2024-07-16 0.25% ≥ 0.259 Low [b4112]

Biomarker Trends

Pancreatic Elastase (Stool) [cb2883]
↓↓ Decline
Decline from 209 to 85 µg/g within 12 months; third value ambiguous.
Bifidobacterium (Stool) [cb602]
→ Severely depleted
Severely depleted on both measurements, approximately 1% of reference lower bound.
Akkermansia Abundance (Stool) [cb201]
↑ Initially below range, subsequently recovered to low-normal
Initially below range, subsequently recovered to low-normal.
Proteobacteria (Stool) [cb3113]
↓↓ Elevated phylum declining
Elevated phylum declining from 11.4% to 0.3% over 16 months.

Clinical Interpretation

Hereditary chronic pancreatitis [d84] driven by a pathogenic PRSS1 variant is the central finding in this system. PRSS1 is causative for autosomal dominant hereditary pancreatitis (~80% penetrance) [w24][w25], and functional pancreatic decline is now manifest: fecal elastase dropped from 209 µg/g [b5265] (borderline adequate) to 85 µg/g [b5266] (severe EPI, <100 µg/g threshold [w152]) within 12 months, consistent with progressive acinar loss [w192]. Active enzyme replacement with pancrelipase (Creon) [m17] addresses digestive function. A third fecal elastase value ("Normal" [b5267] on 2025-12-03) may be confounded by concurrent enzyme supplementation [m17]; Native pancreatic function assessment requires repeat testing off enzyme replacement on formed stool.

Methane-positive SIBO [d67] is confirmed on two separate breath tests with methane well above the diagnostic threshold of ≥10 ppm (16 ppm [b5333] and 27 ppm [b5332]). This is mechanistically linked to the confirmed EPI: loss of pancreatic proteases eliminates antimicrobial defense and triggers ileal brake stasis via undigested macronutrients [w172], while methane further slows transit by up to 59% via cholinergic interference [w190]. The gut microbiome shows severely depleted Bifidobacterium at 0.037–0.041% [cb602] (ref 2.5–5.0%), with initially elevated Proteobacteria that has improved. Mild left colon inflammation (colitis [d9]) and antral gastritis [d10] were documented on endoscopy in 2024-07. Oral microbiome findings (Low Lactobacilli [d2], elevated Parvimonas micra [d3], low S. salivarius [d4], elevated C. rectus [d7]) represent oral dysbiosis that intersects with the periodontitis pattern discussed under Otolaryngologic.

Critically, PRSS1 carriers face a 50- to 87-fold increased risk of pancreatic adenocarcinoma, with annual MRI/MRCP and/or EUS surveillance recommended from age 40 per AGA/ASGE guidelines [w189]. The patient is 55 and this surveillance is absent from the record. No pancreatic morphologic imaging (MRCP/EUS) has been performed to assess for structural changes of chronic pancreatitis.

Medications / Supplements Chart

29 Items
Name Dose Instructions Indication Health benefits Side effects Cautions
▼With Morning Meal15 items
Atorvastatin / Ezetimibe (Atozet) [m30][m51] 20 mg / 10 mg Take with or without food Lowers cholesterol production and absorption
  • Muscle aches
  • GI upset
  • Elevated liver enzymes
  • Monitor: LFTs, CK every 6–12 mo
  • Stop/hold: unexplained muscle pain with dark urine (rhabdomyolysis) → stop immediately [w224]
Irbesartan (Aprovel) [m5] 150 mg — Relaxes blood vessels to lower BP
  • Dizziness
  • Elevated potassium
  • Stop/hold: dehydration, vomiting/diarrhea illness, or surgery → hold to prevent AKI [w224]
  • Monitor: creatinine, potassium annually
Hydrochlorothiazide [m4] 25 mg — Removes excess fluid to lower BP
  • Low potassium
  • Dizziness
  • Sun sensitivity
  • Stop/hold: dehydration, vomiting/diarrhea illness → hold [w224]
  • Monitor: electrolytes, uric acid annually
Metformin (Diabetmin XR) [m21] 500 mg
  • 500 Mg/day at this time (1000 mg/day total
  • See Evening)
 Lowers blood sugar by reducing liver glucose output
  • GI upset
  • B12 depletion with long-term use
  • Stop/hold: illness with vomiting/diarrhea
  • Contrast dye procedures (hold 48 h if eGFR <60)
  • Surgery day [w224]
  • Monitor: B12 annually
Pancrelipase (Creon) [m17] 30,000 units With first bites of meal (10,000 × 3 capsules) Replaces missing digestive enzymes
  • Mouth sores
  • GI cramping
  • Headache
 Pause ≥72 h before fecal elastase recheck
Nicotinamide Riboside Chloride (Tru Niagen) [m62] 1000 mg — Patient-directed — NAD+ support · Keep Boosts NAD+ levels for cellular energy
  • Mild flushing
  • GI upset
 —
B Complex (Doctor's Best) [m15] 1 capsule Contains methylcobalamin 1000 mcg, methylfolate 400 mcg Patient-directed — methylation/B12 · Keep Supports methylation and energy metabolism
  • Bright yellow urine (harmless)
  • Nausea
 Monitor: B12 levels — elevated 766.0 pmol/L [b7360] (ref 156–672) on multi-source intake
Chromium [m10] 100 mcg
  • Picolinate form
  • Pause ≥24 h before OGTT
 Helps cells respond to insulin — —
Alpha Lipoic Acid [m12] 300 mg Pause ≥24 h before OGTT
  • Helps cells use glucose
  • Antioxidant
  • GI upset
  • May lower blood sugar
 Watch: additive glucose-lowering with metformin [m21]
Betaine Anhydrous [m8] 1 g
  • 1 G/day at this time (2 g/day total
  • See Evening)
 Patient-directed — homocysteine · Keep Lowers homocysteine through methylation
  • GI upset
  • Fishy odor
 —
Silymarin (Milk Thistle) [m23] 150 mg
  • 150 Mg at this time (300 mg/day total
  • See Evening)
 Protects liver cells from damage
  • GI upset
  • Rare allergic reaction
 —
Cholecalciferol (Vitamin D3) [m56] 40 mcg (1600 IU) Take with fat-containing food Helps absorb calcium for bones — Monitor: 25(OH)D levels
Vitamin K2 [m36] 120 mcg
  • MK-7 form
  • Take with fat-containing food
 Directs calcium to bones — —
Lutein [m29] 10 mg Take with fat-containing food Protects retina from light damage — —
Zeaxanthin [m39] 2 mg Take with fat-containing food Supports macular health — —
▼Lunchtime1 item
Pancrelipase (Creon) [m17] 30,000 units With first bites of meal (10,000 × 3 capsules) Replaces missing digestive enzymes
  • Mouth sores
  • GI cramping
 —
▼With Evening Meal10 items
Metformin (Diabetmin XR) [m21] 500 mg
  • 500 Mg/day at this time (1000 mg/day total
  • See Morning)
 Lowers blood sugar GI upset See Morning row for full Cautions
Pancrelipase (Creon) [m17] 30,000 units With first bites of meal (10,000 × 3 capsules) Replaces missing digestive enzymes — —
Lobeglitazone [m27] 0.25 mg Half a pill Helps cells respond to insulin
  • Fluid retention
  • Weight gain
 Stop/hold: heart failure flare or severe edema [w224]
Naltrexone [m46] 3 mg
  • Low-dose
  • After dinner
 Supports immune regulation
  • Vivid dreams
  • Mild nausea
 —
Silymarin (Milk Thistle) [m23] 150 mg Second daily dose (300 mg/day total) Protects liver cells — —
Betaine Anhydrous [m8] 1 g Second daily dose (2 g/day total) Patient-directed — homocysteine · Keep Lowers homocysteine — —
DHEA (Douglas Laboratories) [m31] 10 mg Pause ≥7 d before ACTH stimulation test or DHEA-S draw Patient-directed — hormonal support · Keep Supports hormonal balance
  • Acne
  • Oily skin
  • Mood changes
 Watch: confounds DHEA-S [cb1309] and adrenal axis labs
Fish Oil [m13] 2 g 2 softgels (1200 mg EPA+DHA) Patient-directed — TG support · Keep
  • Lowers triglycerides
  • Reduces inflammation
  • Fishy aftertaste
  • GI upset
 —
Cartigenix [m55] 1100 mg — Supports cartilage repair GI upset —
TUDCA [m22] 500 mg — Supports liver detox and bile flow Diarrhea at high doses —
▼Bedtime1 item
Magnesium [m48] 300 mg —
  • Relaxes muscles
  • Supports sleep
 Loose stools at high doses —
▼Non-Daily1 item
Iron [m41] 28 mg
  • Every other day
  • Empty stomach
  • ≥2 H from zinc [m45]
 Supports red blood cell production
  • Constipation
  • Dark stools
  • Nausea
 Monitor: ferritin [cb1632] every 3–6 mo
▼Time per prescriber1 item
Molybdenum [m16] 75 mcg Pause ≥7 d before copper workup Patient-directed — sulfur metabolism cofactor Supports detox enzyme function —
  • Watch: competes at copper metabolic sites
  • Pause timing per copper workup in Copper Metabolism Abnormality

Pending / Conditional New Starts

Items proposed but not yet started — each gated on a specific confirmatory test or specialist direction.
1
Item Proposed dose Gate Indication Rationale
Praziquantel (proposed) 40–60 mg/kg split dose IF Schistosoma CAA/CCA or microscopy positive — per CDC guidelines [w44]
  • Standard antiparasitic for confirmed schistosomiasis
  • Serology alone (IgG index 2.2 [b6018]) insufficient for treatment initiation
  • CDC recommends empiric treatment when exposure is confirmed and antigen testing positive [w44]

Review at Next Visit

Currently in the stack but warrant a prescriber conversation — weak benefit signal, mechanism overlap, or pill burden. Continue unless advised otherwise.
32
Item Current dose & timing Indication Reason to review
Vitamin D [m0] 25 mcg, as directed Patient-directed — bone/immune support
  • Duplicate with cholecalciferol 40 mcg [m56]
  • Verify if both are being taken or one supersedes
1-MNA [m11] 50 mg, as directed Patient-directed — endothelial/NAD+
  • NAD+ pathway overlap with NR 1000 mg [m62]
  • No individual benefit signal in data
Iodine (Potassium Iodide) [m18] 150 mcg, as directed Patient-directed — thyroid support
  • No thyroid finding
  • TSH normal (2.09 miu/L [b6646])
  • No individual benefit signal
L-Theanine [m20] 200 mg, as directed Patient-directed — relaxation No measurable relaxation or anxiety benefit documented in this patient's data
Vitamin B12 [m24] 750 mcg, as directed Patient-directed — methylation
  • Cumulative with B Complex [m15] yields ~1750 mcg/day
  • B12 elevated (843 pmol/L, ref 156–672)
  • Consider reducing to single source
Astaxanthin [m25] 8 mg, daily Patient-directed — antioxidant
  • Antioxidant mechanism overlaps with ≥5 other items in stack (NAC, Vit C, pine bark, tocotrienols, MitoQ)
  • No individual [bN] improvement signal
Saffron Extract [m26] 15 mg, as directed Patient-directed — mood/appetite No measurable mood or appetite benefit documented in data
Mitoquinol Mesylate (MitoQ) [m28] 20 mg, as directed Patient-directed — mitochondrial antioxidant
  • Mitochondrial mechanism overlap with NR [m62] and urolithin A [m37]
  • No individual signal separate from NR's NAD+ improvement
Proanthocyanidins (Pine Bark) [m33] 100 mg twice daily Patient-directed — antioxidant/circulation
  • Antioxidant mechanism overlap with multiple stack items
  • No individual benefit signal
L-Taurine [m34] 750 mg twice daily Patient-directed — cardiac/nervous support No measurable cardiac or nervous system benefit signal in [bN]
L-Glycine [m35] 3 g, bedtime Patient-directed — sleep support No measurable sleep benefit signal in data
Urolithin A (Mitopure) [m37] 500 mg, as directed Patient-directed — mitochondrial renewal
  • Mitochondrial mechanism overlap
  • No individual benefit signal
Acetyl-L-carnitine [m42] 1 g, daily Patient-directed — mitochondrial/cognitive
  • Mitochondrial/cognitive mechanism overlap
  • No individual benefit signal
L-Selenomethionine [m44] 100 mcg, as directed Patient-directed — thyroid/antioxidant
  • No thyroid finding
  • TSH normal
  • No individual benefit signal
Ascorbic Acid (Vitamin C) [m47] 500 mg, daily Patient-directed — immune/antioxidant
  • Antioxidant mechanism overlap
  • No individual benefit signal beyond general nutrition
  • Total Vit C from multiple sources
Caprylic Acid [m49] 600 mg, as directed Patient-directed — antimicrobial
  • SIBO management being referred to GI specialist
  • No individual benefit signal from this supplement
Tocotrienols (Vitamin E) [m53] 150 mg, as directed Patient-directed — lipid antioxidant
  • Antioxidant mechanism overlap
  • No individual benefit signal
Psyllium Husk [m54] 500 mg, bedtime Patient-directed — fiber/cholesterol
  • LDL already 1.1 mmol/L on statin
  • Marginal additional cholesterol benefit
  • GI transit role better directed by GI specialist in SIBO context
Manganese [m57] 1 mg, as directed Patient-directed — connective tissue
  • No individual benefit signal
  • Pill burden contribution
Cytidine Diphosphate Choline [m58] 250 mg twice daily Patient-directed — cognitive support
  • Choline pathway overlap with phosphatidylcholine [m43]
  • No measurable cognitive benefit signal
Lion's Mane Mushroom [m59] 500 mg twice daily Patient-directed — cognitive support
  • No measurable cognitive benefit signal in [bN]
  • Brain age (53 y [b1362]) younger than chronological age
Qualia Senolytic [m63] As directed, 2 days/month Patient-directed — cellular rejuvenation
  • Novel senolytic mechanism
  • No measurable benefit signal in data
Vitamin C [m65] 50 mg, with collagen Patient-directed — collagen absorption
  • Minimal standalone dose
  • Combined with collagen [m7] which also lacks benefit signal
Collagen [m7] 15 g, before morning swim Patient-directed — connective tissue No measurable joint/connective tissue benefit in [bN] despite extensive MSK disease
Spermidine [m67] 1 mg, daily Patient-directed — autophagy support No measurable autophagy or cellular benefit signal in data
Ashwagandha (Sensoril) [m9] 250 mg, evening Patient-directed — stress support
  • HPA axis confounder
  • Confounds cortisol [cb1163][cb1180] measurements
  • No documented cortisol benefit in this patient's data
  • Pause ≥5 d before any ACTH stimulation test
Magnolia Bark [m60] 400 mg, bedtime Patient-directed — sleep/relaxation
  • HPA axis confounder
  • Confounds cortisol measurements
  • No documented sleep benefit in data
  • Pause ≥3 d before any ACTH stimulation test
Phosphatidylserine [m38] 200 mg, evening Patient-directed — cortisol support
  • HPA axis confounder
  • Confounds cortisol measurements
  • No documented cortisol-dampening benefit in data
  • Pause ≥3 d before any ACTH stimulation test
Aged Garlic Extract (Kyolic) [m64] 1 g, evening Patient-directed — BP support
  • No documented BP improvement signal in [bN]
  • BP incompletely controlled on dual therapy (nocturnal systolic 128 mmHg [b6474])
N-Acetylcysteine (NAC) [m52] 600 mg twice daily (morning + evening) Patient-directed — liver support
  • Liver-support mechanism overlaps silymarin [m23] and TUDCA [m22], which have per-condition Continue bullets
  • No individual [bN] liver benefit signal
Phosphatidylcholine [m43] 1 g, evening Patient-directed — liver support
  • Liver-support mechanism overlap with silymarin [m23] and TUDCA [m22]
  • No individual [bN] liver benefit signal
Zinc [m45] 15 mg, evening Patient-directed — immune support

Do Not Start

Not currently in the stack and should not be prescribed — non-obvious contraindications driven by findings a referring specialist might not see. Flag to any future doctor.
2
Drug / class Reason Driven by finding See
Bisphosphonates / Denosumab (anti-resorptive bone therapy) Both bone formation (osteocalcin 11.0 µg/L [b4840]) and resorption (Beta-CrossLaps 50–137 ng/L [cb590]) are already suppressed — anti-resorptives would further impair micro-damage repair and increase atypical fracture risk [w229]. EPI-driven secondary causes must be addressed first. Osteopenia [d76] + low bone turnover [cb2634][cb590] Degenerative Musculoskeletal Disease
NSAIDs (oral, including ibuprofen, naproxen, diclofenac)
  • Concurrent ARB [m5] + thiazide diuretic [m4] + mildly reduced eGFR 70–86 mL/min [cb1575] creates high AKI risk
  • Would also worsen hypertension [d79]
  • Hypertension [d79]
  • eGFR [cb1575]
 Degenerative Musculoskeletal Disease

To Be Discontinued

Active items recommended for discontinuation.
4
Item Was dose Was indication Reason for stop
Bergamot Orange [m19] 500 mg daily Patient-directed — cholesterol support
Quercetin Phytosome [m50] 250 mg, as directed Patient-directed — anti-inflammatory
Nattokinase [m40] 4000 FU every other day Patient-directed — clotting/circulation
  • Confounds coagulation panel interpretation
  • aPTT remains shortened despite use
  • No clinician indication
  • See Hypercoagulable Pattern
Lumbrokinase [m61] 20 mg, as directed Patient-directed — clotting/circulation

Reviewed Without Action

Items reviewed during this analysis that do not require new actions — surfaced for completeness so future readers know they were considered.
3
Low Priority / Surveillance Only
  • Elevated Total IgE with Dust Mite Sensitization [cb2066]
    • Asymptomatic sensitization in 20–25% of adults [w183]
    • No intervention warranted without allergic symptoms
  • NSUN2 Heterozygous Carrier Status [d85]
    • Carrier status only
    • Biallelic variants required for clinical MRT5 [w48]
    • Reproductive counseling if desired
  • Mildly Elevated HVA/VMA Ratio [cb1982]
    • 1.5 Mmol/mol [b3611] (ref 0.32–1.4)
    • No catecholamine excess symptoms
    • No workup warranted in isolation

Summary & Recommendations Recap

A plain-language wrap-up of your health picture and the concrete next steps — every action links back to the section that explains it.
Your Health Picture

Your health is shaped by two main connected problems working together. First, you carry a gene change (PRSS1) that causes hereditary pancreatitis — your pancreas is gradually losing its ability to produce digestive enzymes, which has dropped into the severe range over the past year. This enzyme loss makes it harder for your body to absorb fats and fat-soluble vitamins, which is contributing to bone thinning and may be driving bacterial overgrowth in your gut. Second, you have a cluster of heart-related risk factors — high blood pressure, borderline-high blood sugar with strong insulin resistance, and a pattern of small dense cholesterol particles — that together have produced early plaque in your coronary arteries and fatty changes in your liver, despite your lean build.

A key question remains unanswered: whether your blood sugar problem comes from your pancreas disease (a form called Type 3c diabetes) or is a separate Type 2 diabetes. This matters because the two require different long-term strategies. You also have advanced gum disease with aggressive bacteria, which is a known contributor to heart and artery disease. Your blood clotting system shows a persistent pattern of being overactive, which needs specialist evaluation — complicated by the fact that two supplements you take (nattokinase and lumbrokinase) make the blood tests hard to interpret.

Your supplement stack is very large at 67 items, with several groups of supplements doing essentially the same thing. About 32 of these lack measurable evidence of benefit in your lab results and should be reviewed with your prescriber to reduce pill burden and interaction risk.

System-by-System Status
  • Gastrointestinal CONCERNING Severe pancreatic enzyme deficiency on enzyme replacement; Confirmed methane-positive SIBO linked to the enzyme loss; Cancer surveillance critically overdue for your gene variant.
  • Musculoskeletal CONCERNING Advanced bone thinning approaching osteoporosis at the hip; Cervical disc prolapses pressing on nerve roots; Bilateral rotator cuff tears; Low bone turnover precludes standard bone-strengthening drugs until workup completes.
  • Oral Health CONCERNING Advanced gum disease with aggressive bacteria; Needs specialist restaging and treatment plan; Compounds heart disease risk.
  • Endocrine/Metabolic FAIR Blood sugar controlled in the prediabetes range on medication; Insulin resistance marked but managed; Cortisol findings contradictory and heavily confounded by supplements.
  • Cardiovascular FAIR Blood pressure partially controlled with elevated nighttime readings; Mild coronary plaque present; Cholesterol well controlled on treatment; Possible heart wall thickening needs echocardiogram confirmation.
  • Blood/Clotting FAIR Persistently short clotting time with elevated clotting factors suggesting overactive system; Needs hematology evaluation after stopping confounding supplements.
  • Lung Function FAIR Reduced lung volumes on a single test from 2 years ago; Needs confirmatory testing to determine if truly restricted.
  • Liver/Gallbladder FAIR Fatty liver from insulin resistance; Gallstone and small polyps need annual ultrasound; Copper metabolism abnormality needs workup to rule out Wilson disease.
  • Immune System FAIR Premature immune aging driven by chronic CMV virus; On low-dose naltrexone.
  • Kidney/Urological FAIR Mildly reduced kidney filtration (not CKD); Bladder wall changes suggest possible outlet issue; Needs symptom assessment.
  • Infectious Disease GOOD All positive blood tests show past exposure, not confirmed active infections; Schistosoma needs confirmatory testing.
  • Eyes GOOD Mild dry-eye gland issue; No diabetic eye damage.
  • Neurological GOOD Gene carrier status only; No brain or nerve disease.
What To Do Next
Labs to Order 14
Referrals 7
Stop 4
Pause Before Labs 6
Watch / Monitor 4
  • Watch for low blood sugar symptoms (shakiness, sweating, confusion) — FPG 3.0 mmol/L [b2792] occurred on current glucose-lowering regimen → see Cardiometabolic Syndrome
  • Watch for kidney stone symptoms (flank pain, blood in urine) — urinary oxalate elevated from EPI-related malabsorption → see Hereditary Chronic Pancreatitis
  • Watch ferritin trend — declining despite iron supplementation; Report persistent fatigue or shortness of breath → see Hereditary Chronic Pancreatitis
  • Watch for low cortisol symptoms (fatigue, dizziness on standing, unexplained weight loss) — report promptly → see HPA Axis Findings
Sick-Day / Hold Rules 4
  • Hold metformin [m21] during illness with vomiting/diarrhea; Hold for contrast procedures (48 h if eGFR <60); Hold on surgery day [w224] → see Medication & Supplement
  • Hold irbesartan [m5] and hydrochlorothiazide [m4] during dehydrating illness or before surgery [w224] → see Medication & Supplement
  • Stop atorvastatin [m30] immediately if unexplained muscle pain with dark urine (rhabdomyolysis warning) [w224] → see Medication & Supplement
  • Hold lobeglitazone [m27] if heart failure symptoms or severe swelling develop [w224] → see Medication & Supplement
Do Not Start 2

References

Citation Key

[wN] Web research
[dN] Diagnosis
[pN] Procedure
[mN] Medication/Supplement
[bN] Biomarker test
[cbN] Canonical biomarker

A. Patient Evidence

A1. Biomarker Groups

Ceruloplasmin [in Serum/Plasma]
[cb1025]

Unit: g/l  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b1754] CAERULOPLASMIN 0.18 g/l 0.15 - 0.3 2024-05-14 Normal redacted 2
[b1755] Serum Ceruloplasmin 0.16 g/l 0.15 - 0.3 2024-10-12 Normal redacted 1
[b1756] Caeruloplasmin 0.18 g/l 0.15 - 0.3 2024-12-16 Normal redacted 6
[b1757] Caeruloplasmin 0.17 g/l 0.24 - 0.6 2026-01-22 Abnormal redacted 6
[b1758] Ceruloplasmin 0.16 g/l 0.2 - 0.6 2026-04-07 Abnormal redacted 14
Chlamydia pneumoniae (EliSpot) [in Whole Blood]
[cb1054]

Unit: si  ·  Sample: Whole Blood

Ref Test Name Result Ref Range Date Status Source Page
[b1792] Chlamydia pneumoniae-EliSpot 2.0 si 0.0 - 1.0 2025-08-21 Abnormal redacted 2
Citrate Synthase/Protein (Buccal) [nanomoles/min/mg buccal protein] [in Buccal]
[cb1081]

Unit: nanomoles/min/mg buccal protein  ·  Sample: Buccal

Ref Test Name Result Ref Range Date Status Source Page
[b1851] Citrate Synthase 42.96 nanomoles/min/mg buccal protein 4.4 - 22.0 2025-10-09 Abnormal redacted 1
Copper (ICPMS) [in Serum/Plasma]
[cb1144]

Unit: umol/l  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b1948] Copper, serum (ICPMS) 9.095 umol/l 11.802 - 22.817 2026-04-03 Abnormal redacted 12
Coronary Artery Calcium Score [in Coronary Arteries]
[cb1160]

Unit: score  ·  Sample: Coronary Arteries

Ref Test Name Result Ref Range Date Status Source Page
[b1973] Coronary Artery Calcium Score 19.0 score N/A 2024-07-15 Abnormal redacted 6
[b1974] Calcium Score 19.00 score N/A 2024-07-15 - redacted 38
Cortisol [in Serum/Plasma]
[cb1163]

Unit: nmol/l  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b1980] Cortisol 307.0 nmol/l 95.0 - 462.0 2025-03-12 Normal redacted 6
[b1983] Cortisol 298.0 nmol/l 145.0 - 619.0 2025-05-23 Normal redacted 8
[b1979] Cortisol 397.0 nmol/l 145.0 - 619.0 2025-06-23 Normal redacted 4
[b1981] Cortisol 323.0 nmol/l AM: 145-619; PM: 95-462 2025-07-08 Normal redacted 4
[b1982] Cortisol 361.0 nmol/l 145.0 - 619.0 2025-09-04 Normal redacted 4
[b1984] Cortisol 365.0 nmol/l 95.0 - 619.0 2025-10-17 Normal redacted 9
[b1985] Cortisol 34.0 nmol/l 145.0 - 619.0 2026-01-10 Abnormal redacted 4
[b1986] Cortisol 190.0 nmol/l 145.0 - 619.0 2026-04-03 Normal redacted 7
Cortisol (Morning, Saliva) [in Saliva]
[cb1180]

Unit: nmol/l  ·  Sample: Saliva

Ref Test Name Result Ref Range Date Status Source Page
[b2007] Cortisol Profile, Morning 11.1 nmol/l 12.0 - 48.0 2024-05-11 Abnormal redacted 1
Coxsackievirus A7 IgA (IFT) [in Serum/Plasma]
[cb1211]

Unit: ratio  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b2045] Coxsackie-IgA Type A7 (IFT) 100.0 ratio <= 10.0 2025-07-22 Abnormal redacted 8
Coxsackievirus B1 IgA (IFT) [in Serum/Plasma]
[cb1215]

Unit: ratio  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b2049] Coxsackie-IgA Type B1 (IFT) 100.0 ratio <= 10.0 2025-07-22 Abnormal redacted 8
Cystatin C [in Serum/Plasma]
[cb1278]

Unit: mg/l  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b2168] Cystatin C 0.9 mg/l <= 0.85 2024-09-25 Abnormal redacted 5
[b2169] CYSTATIN C 0.82 mg/l 0.64 - 1.23 2025-03-15 Normal redacted 4
[b2170] Cystatin C 0.83 mg/l <= 0.85 2025-10-17 Normal redacted 8
[b2171] CYSTATIN C 0.85 mg/l 0.64 - 1.23 2025-11-30 Normal redacted 3
Cytomegalovirus IgG (ELISA) [in Serum/Plasma]
[cb1290]

Unit: ratio  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b2187] CMV IgG antibodies (ELISA) 3.686 ratio Negative 2025-07-22 Abnormal redacted 6
Cytomegalovirus Latent (EliSpot) [in Whole Blood]
[cb1294]

Unit: si  ·  Sample: Whole Blood

Ref Test Name Result Ref Range Date Status Source Page
[b2191] CMV Latent 160.0 si 0.0 - 1.0 2025-08-21 Abnormal redacted 4
D-Dimer [in Whole Blood]
[cb1297]

Unit: ng/ml  ·  Sample: Whole Blood

Ref Test Name Result Ref Range Date Status Source Page
[b2194] D-Dimer 0.56 ng/ml <= 0.5 2024-10-14 Abnormal redacted 1
[b2195] D-Dimer 585.0 ng/ml <= 500.0 2024-10-14 Abnormal redacted 1
[b2197] D-Dimer Auto 0.56 ng/ml <= 0.5 2024-10-14 Abnormal redacted 1
[b2196] D-Dimer 629.0 ng/ml <= 500.0 2024-10-17 Abnormal redacted 2
[b2198] D-Dimer 320.0 ng/ml 0.0 - 500.0 2025-03-12 Normal redacted 2
[b2199] D-Dimer 270.0 ng/ml 0.0 - 500.0 2025-05-23 Normal redacted 2
[b2200] D-Dimer 570.0 ng/ml 0.0 - 500.0 2025-10-17 Abnormal redacted 2
[b2201] D-Dimer 270.0 ng/ml 0.0 - 500.0 2025-12-08 Normal redacted 2
Dehydroepiandrosterone Sulfate (DHEA-S) [in Serum/Plasma]
[cb1309]

Unit: umol/l  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b2217] DHEA - Sulphate 7.2 umol/l 2.2 - 15.2 2024-09-25 Normal redacted 6
[b2221] DHEA Sulphate 3.0 umol/l 1.2 - 11.6 2024-12-16 Normal redacted 5
[b2219] DHEA - Sulphate 12.0 umol/l 2.2 - 15.2 2024-12-27 Normal redacted 5
[b2220] DHEA - Sulphate 12.0 umol/l 2.2 - 15.2 2025-03-12 Normal redacted 6
[b2216] DHEA - Sulphate 2.1 umol/l 2.2 - 15.2 2025-05-23 Abnormal redacted 8
[b2223] DHEA - Sulphate 2.5 umol/l 2.2 - 15.2 2025-06-23 Normal redacted 4
[b2218] DHEA - Sulphate 1.9 umol/l 3.7 - 12.2 2025-07-08 Abnormal redacted 4
[b2222] DHEA - Sulphate 2.7 umol/l 3.7 - 12.2 2025-09-04 Abnormal redacted 4
[b2224] DHEA - Sulphate 3.9 umol/l 3.7 - 12.2 2025-10-17 Normal redacted 9
[b2225] DHEA - Sulphate 1.3 umol/l 1.3 - 9.8 2026-01-10 Normal redacted 4
[b2226] DHEA Sulphate 3.4 umol/l 0.9 - 8.0 2026-01-22 Normal redacted 5
[b2227] DHEA - Sulphate 2.8 umol/l 1.3 - 9.8 2026-04-03 Normal redacted 8
Dermatophagoides farinae IgE [iu/ml] [in Serum/Plasma]
[cb1371]

Unit: iu/ml  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b2298] D. farinae 2.13 iu/ml 0.0 - 0.35 2026-04-03 Abnormal redacted 2
Dermatophagoides pteronyssinus IgE [in Serum/Plasma]
[cb1375]

Unit: iu/ml  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b2302] D. pteronyssinus 0.91 iu/ml 0.0 - 0.35 2026-04-03 Abnormal redacted 2
Des-Gamma-Carboxy Prothrombin (Elecsys) [in Serum/Plasma]
[cb1378]

Unit: ug/l  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b2305] PIVKA-II (Elecsys) 62.3 ug/l <= 28.4 2025-03-15 Abnormal redacted 6
[b2306] PIVKA-II (Elecsys) 21.0 ug/l <= 28.4 2025-11-30 Normal redacted 5
Diabetic Retinopathy (Left Eye) [in Eye]
[cb1386]

Unit: N/A  ·  Sample: Eye

Ref Test Name Result Ref Range Date Status Source Page
[b2316] Diabetic Retinopathy (Left Eye) Negative N/A N/A 2025-11-29 - redacted 2
Diabetic Retinopathy (Right Eye) [in Eye]
[cb1387]

Unit: N/A  ·  Sample: Eye

Ref Test Name Result Ref Range Date Status Source Page
[b2317] Diabetic Retinopathy (Right Eye) Negative N/A N/A 2025-11-29 - redacted 2
Diastolic Blood Pressure (Night) [in Arterial System]
[cb1395]

Unit: mmhg  ·  Sample: Arterial System

Ref Test Name Result Ref Range Date Status Source Page
[b2371] Diastolic Blood Pressure (Night-time) 82.0 mmhg 65.0 - 70.0 2025-09-01 Abnormal redacted 1
[b2372] Diastolic Blood Pressure (Night-time) 69.0 mmhg 65.0 - 70.0 2025-09-01 Normal redacted 1
[b2373] Diastolic Blood Pressure (Night-time) 62.0 mmhg 65.0 - 70.0 2025-09-01 Abnormal redacted 1
Enterococcus faecalis (Saliva) [in Saliva]
[cb1512]

Unit: cfu/ml  ·  Sample: Saliva

Ref Test Name Result Ref Range Date Status Source Page
[b2535] Enterococcus faecalis 13360.0 cfu/ml <= 1000.0 2025-11-17 Abnormal redacted 1
Estimated Glomerular Filtration Rate (eGFR) [in Serum/Plasma]
[cb1573]

Unit: ml/min  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b2706] eGFR 102.0 ml/min >= 90.0 2024-10-12 Normal redacted 2
[b2707] Estimated GFR 72.0 ml/min >= 90.0 2024-12-16 Abnormal redacted 4
[b2705] EGFR 92.0 ml/min >= 90.0 2025-03-15 Normal redacted 3
[b2708] EGFR 70.0 ml/min >= 90.0 2025-11-30 Abnormal redacted 3
[b2709] Estimated GFR 86.0 ml/min >= 90.0 2026-01-22 Abnormal redacted 4
Estimated Glomerular Filtration Rate (eGFR, CKD-EPI) [in Serum/Plasma]
[cb1575]

Unit: ml/min  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b2711] Estimated - GFR (CKD-EPI) 84.0 ml/min >= 90.0 2024-09-25 Abnormal redacted 4
[b2712] Estimated - GFR (CKD-EPI) 80.0 ml/min >= 90.0 2024-12-27 Abnormal redacted 4
[b2714] Estimated - GFR (CKD-EPI) >90 ml/min >= 90.0 2025-03-12 Normal redacted 3
[b2717] Estimated - GFR (CKD-EPI) 87.0 ml/min >= 90.0 2025-05-23 Abnormal redacted 5
[b2713] Estimated - GFR (CKD-EPI) >90 ml/min >= 90.0 2025-06-23 Normal redacted 3
[b2716] Estimated - GFR (CKD-EPI) >90 ml/min >= 90.0 2025-07-08 Normal redacted 3
[b2715] Estimated - GFR (CKD-EPI) 87.0 ml/min >= 90.0 2025-09-04 Abnormal redacted 3
[b2718] Estimated - GFR (CKD-EPI) >90 ml/min >= 90.0 2025-10-17 Normal redacted 6
[b2720] Estimated - GFR (CKD-EPI) 85.0 ml/min >= 90.0 2025-12-08 Abnormal redacted 5
[b2719] Estimated Glomerular Filtration Rate (CKD-EPI) >90 ml/min >= 90.0 2026-01-10 Normal redacted 3
[b2721] Estimated - GFR (CKD-EPI) 84.0 ml/min >= 90.0 2026-04-03 Abnormal redacted 4
Activated Partial Thromboplastin Time (aPTT) [in Whole Blood]
[cb157]

Unit: s  ·  Sample: Whole Blood

Ref Test Name Result Ref Range Date Status Source Page
[b278] APTT 22.0 s 22.1 - 28.1 2024-10-17 Abnormal redacted 1
[b279] APTT 15.7 s 22.9 - 32.1 2024-12-27 Abnormal redacted 2
[b280] APTT 19.3 s 22.9 - 32.1 2025-03-12 Abnormal redacted 2
[b281] APTT 19.6 s 22.9 - 32.1 2025-05-23 Abnormal redacted 2
[b277] APTT-Patient 26.5 s N/A 2025-09-01 Abnormal redacted 5
[b282] APTT 17.2 s 22.9 - 32.1 2025-10-17 Abnormal redacted 2
[b283] APTT 17.9 s 22.9 - 32.1 2025-12-08 Abnormal redacted 2
[b284] Activated Partial Thromboplastin Time (APTT) 20.1 s 22.9 - 32.1 2026-04-03 Abnormal redacted 2
FEV1/IVC Ratio [in Respiratory System]
[cb1603]

Unit: %  ·  Sample: Respiratory System

Ref Test Name Result Ref Range Date Status Source Page
[b2776] FEV1%VCin 77.67 % >= 113.84 2024-07-15 Abnormal redacted 29
Factor VIII Activity [in Whole Blood]
[cb1609]

Unit: %  ·  Sample: Whole Blood

Ref Test Name Result Ref Range Date Status Source Page
[b2782] Factor VIII:C 162.4 % 50.0 - 150.0 2025-09-01 Abnormal redacted 5
Fasting Glucose [in Serum/Plasma]
[cb1612]

Unit: mmol/l  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b2787] Glucose 5.5 mmol/l 4.1 - 6.1 2024-04-24 Normal redacted 1
[b2800] Glucose 5.2 mmol/l N/A 2024-07-15 - redacted 38
[b2801] Fasting Glucose 5.2 mmol/l <= 6.1 2024-07-15 Normal redacted 10
[b2788] Glucose 4.4 mmol/l 3.9 - 6.0 2024-09-25 Normal redacted 4
[b2791] Glucose 4.9 mmol/l 3.9 - 6.0 2024-10-12 Normal redacted 2
[b2794] GLUCOSE (FASTING) 5.3 mmol/l 3.0 - 5.4 2024-12-16 Normal redacted 3
[b2789] Glucose 4.0 mmol/l 3.9 - 6.0 2024-12-27 Normal redacted 4
[b2793] Glucose 4.7 mmol/l 3.9 - 6.0 2025-03-12 Normal redacted 3
[b2796] Glucose 4.8 mmol/l 3.9 - 6.0 2025-05-23 Normal redacted 5
[b2795] Glucose 4.4 mmol/l 3.9 - 6.0 2025-07-08 Normal redacted 3
[b2790] Fasting Glucose Normal mmol/l N/A 2025-08-19 Normal redacted 11
[b2792] Glucose 3.0 mmol/l 3.9 - 6.0 2025-09-04 Abnormal redacted 3
[b2797] Fasting Glucose 4.9 mmol/l N/A 2025-10-17 - redacted 14
[b2798] Glucose 4.9 mmol/l 3.9 - 6.0 2025-10-17 Normal redacted 5
[b2803] Glucose 4.6 mmol/l 3.9 - 6.0 2025-12-08 Normal redacted 5
[b2799] Glucose 7.2 mmol/l 3.9 - 6.0 2026-01-10 Abnormal redacted 1
[b2802] Glucose 5.1 mmol/l 3.9 - 6.0 2026-01-10 Normal redacted 3
[b2804] Glucose (Fasting) 4.7 mmol/l 3.0 - 5.4 2026-01-22 Normal redacted 3
[b2805] Glucose 4.3 mmol/l 3.9 - 6.0 2026-04-03 Normal redacted 4
Fat-Free Mass Index [in Patient]
[cb1619]

Unit: kg/m^2  ·  Sample: Patient

Ref Test Name Result Ref Range Date Status Source Page
[b2814] Fat-Free Mass Index (FFMI) 16.7 kg/m^2 >= 17.0 2024-07-15 Abnormal redacted 39
Ferritin [in Serum/Plasma]
[cb1632]

Unit: ug/l  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b2832] Ferritin 84.7 ug/l 22.0 - 322.0 2024-09-25 Normal redacted 5
[b2833] Ferritin 88.0 ug/l 20.0 - 300.0 2024-10-12 Normal redacted 3
[b2831] Ferritin 92.5 ug/l 22.0 - 322.0 2024-11-06 Normal redacted 2
[b2836] Ferritin 101.0 ug/l 30.0 - 400.0 2024-12-16 Normal redacted 4
[b2835] Ferritin 36.0 ug/l 22.0 - 322.0 2025-03-12 Normal redacted 5
[b2834] FERRITIN 32.0 ug/l 22.0 - 322.0 2025-03-15 Normal redacted 2
[b2837] Ferritin 32.3 ug/l 22.0 - 322.0 2025-05-23 Normal redacted 7
[b2830] Ferritin 17.7 ug/l 22.0 - 322.0 2025-10-17 Abnormal redacted 8
[b2838] FERRITIN 19.0 ug/l 22.0 - 322.0 2025-11-30 Abnormal redacted 1
[b2839] Ferritin 24.5 ug/l 22.0 - 322.0 2025-12-08 Normal redacted 7
[b2840] Ferritin 43.0 ug/l 30.0 - 300.0 2026-01-22 Normal redacted 4
[b2841] Ferritin 27.4 ug/l 22.0 - 322.0 2026-04-03 Normal redacted 6
Forced Expiratory Volume in 1 Second (FEV1) [in Respiratory System]
[cb1660]

Unit: l  ·  Sample: Respiratory System

Ref Test Name Result Ref Range Date Status Source Page
[b2914] FEV 1 3.07 l >= 4.61 2024-07-15 Abnormal redacted 29
Forced Vital Capacity (FVC) [in Respiratory System]
[cb1662]

Unit: l  ·  Sample: Respiratory System

Ref Test Name Result Ref Range Date Status Source Page
[b2917] FVC 3.83 l >= 5.25 2024-07-15 Abnormal redacted 29
Free Copper Percentage [in Serum/Plasma]
[cb1669]

Unit: %  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b2932] % Free Copper 42.0 % 5.0 - 25.0 2024-05-14 Abnormal redacted 2
[b2933] % Free Copper 34.0 % 5.0 - 25.0 2024-12-16 Abnormal redacted 6
[b2934] % Free Copper 44.0 % 5.0 - 25.0 2026-01-22 Abnormal redacted 6
Fusobacterium nucleatum [in Xxx]
[cb1698]

Unit: copies/ml  ·  Sample: Xxx

Ref Test Name Result Ref Range Date Status Source Page
[b3032] Fusobacterium nucleatum (Fn) Above Reference Lines copies/ml Mean bacterial level observed in patients with chronic periodontitis AAP Stage I-II 2026-01-20 Abnormal redacted 3
Grip Strength (Percentile) [in Patient]
[cb1848]

Unit: percentile  ·  Sample: Patient

Ref Test Name Result Ref Range Date Status Source Page
[b3278] Grip Strength Percentile 39.0 percentile ≥ 50th percentile 2025-05-13 Abnormal redacted 15
[b3277] Grip Strength Percentile 52.3 percentile 0-100 percentile 2025-08-19 Normal redacted 9
Haptoglobin [in Serum/Plasma]
[cb1877]

Unit: g/l  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b3331] Haptoglobin 0.26 g/l 0.4 - 2.4 2025-10-17 Abnormal redacted 5
Heart Age [in ^Patient]
[cb1883]

Unit: y  ·  Sample: ^Patient

Ref Test Name Result Ref Range Date Status Source Page
[b3338] Heart System Age 55.5 y <= 54.7 2025-08-19 Abnormal redacted 4
Hemoglobin A1c (HbA1c) [in Whole Blood]
[cb1925]

Unit: mmol/mol  ·  Sample: Whole Blood

Ref Test Name Result Ref Range Date Status Source Page
[b3480] HbA1C 43.169 mmol/mol N/A 2024-07-15 - redacted 1
[b3481] Haemoglobin A1C [NGSP] 36.612 mmol/mol <= 47.541 2024-07-15 Normal redacted 10
[b3482] Haemoglobin A1C [IFCC] 37.0 mmol/mol <= 48.0 2024-07-15 Normal redacted 10
[b3470] HbA1c (IFCC) 37.0 mmol/mol <= 39.0 2024-10-12 Normal redacted 3
[b3471] HbA1c 36.612 mmol/mol <= 38.798 2024-10-12 Normal redacted 3
[b3472] Glycated Haemoglobin (HbA1c) 37.0 mmol/mol <= 39.0 2025-03-12 Normal redacted 4
[b3473] Glycated Haemoglobin (HbA1c) 36.612 mmol/mol <= 38.798 2025-03-12 Normal redacted 4
[b3468] HBA1C 39.0 mmol/mol <= 39.0 2025-03-15 Normal redacted 2
[b3469] HBA1C 38.798 mmol/mol <= 38.798 2025-03-15 Normal redacted 2
[b3474] Glycated Hemoglobin (HbA1c) 37.705 mmol/mol <= 38.798 2025-05-23 Normal redacted 6
[b3475] Glycated Hemoglobin (HbA1c) 38.0 mmol/mol <= 39.0 2025-05-23 Normal redacted 6
[b3484] HbA1c, NGSP unit 36.612 mmol/mol <= 38.798 2025-10-08 Normal redacted 6
[b3485] HbA1c, SI unit 37.0 mmol/mol <= 39.0 2025-10-08 Normal redacted 6
[b3477] Glycated Haemoglobin (HbA1c) 38.0 mmol/mol <= 39.0 2025-10-17 Normal redacted 7
[b3478] Glycated Haemoglobin (HbA1c) 37.705 mmol/mol <= 38.798 2025-10-17 Normal redacted 7
[b3476] Hemoglobin A1c 40.984 mmol/mol N/A 2025-11-29 - redacted 2
[b3479] HBA1C 37.705 mmol/mol <= 38.798 2025-11-30 Normal redacted 2
[b3483] HBA1C 38.0 mmol/mol <= 39.0 2025-11-30 Normal redacted 2
[b3486] HbA1c, NGSP unit 36.612 mmol/mol <= 38.798 2026-04-03 Normal redacted 5
[b3487] HbA1c, SI unit 37.0 mmol/mol <= 39.0 2026-04-03 Normal redacted 5
Aggregatibacter actinomycetemcomitans [in Unspecified]
[cb192]

Unit: N/A  ·  Sample: Unspecified

Ref Test Name Result Ref Range Date Status Source Page
[b344] Aggregatibacter actinomycetemcomitans Quantity 15500 N/A <10000 2026-01-26 Abnormal redacted 4
Homocysteine [in Serum/Plasma]
[cb1973]

Unit: umol/l  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b3581] Homocysteine 10.4 umol/l 5.0 - 15.0 2024-05-14 Normal redacted 2
[b3582] Homocysteine 19.24 umol/l 3.7 - 13.9 2024-09-25 Abnormal redacted 8
[b3587] Homocysteine 12.2 umol/l 5.0 - 15.0 2024-12-16 Normal redacted 3
[b3584] Homocysteine 20.08 umol/l 3.7 - 13.9 2024-12-27 Abnormal redacted 6
[b3586] Homocysteine 15.93 umol/l 10.0 - 29.0 2025-03-12 Normal redacted 7
[b3585] HOMOCYSTEINE 10.9 umol/l 5.0 - 15.0 2025-03-15 Normal redacted 4
[b3590] Homocysteine 19.34 umol/l 10.0 - 29.0 2025-05-23 Normal redacted 9
[b3589] Homocysteine 19.8 umol/l 10.0 - 29.0 2025-06-23 Normal redacted 5
[b3583] Homocysteine 15.32 umol/l 10.0 - 29.0 2025-07-08 Normal redacted 5
[b3588] Homocysteine 19.31 umol/l 10.0 - 29.0 2025-09-04 Normal redacted 5
[b3591] Homocysteine 16.32 umol/l 10.0 - 29.0 2025-10-17 Normal redacted 10
[b3592] HOMOCYSTEINE 9.1 umol/l 5.0 - 15.0 2025-11-30 Normal redacted 4
[b3594] Homocysteine 19.05 umol/l 10.0 - 29.0 2025-12-08 Normal redacted 7
[b3593] Homocysteine 12.29 umol/l 10.0 - 29.0 2026-01-10 Normal redacted 5
[b3595] Homocysteine 8.9 umol/l 5.0 - 15.0 2026-01-22 Normal redacted 3
[b3596] Homocysteine 15.45 umol/l 10.0 - 29.0 2026-04-03 Normal redacted 8
Homovanillic Acid/Vanillylmandelic Acid Ratio (Urine) [in Urine]
[cb1982]

Unit: mmol/mol  ·  Sample: Urine

Ref Test Name Result Ref Range Date Status Source Page
[b3610] HVA/VMA 1500.0 mmol/mol N/A 2025-07-29 Abnormal redacted 7
[b3611] HVA / VMA Ratio 1.5 mmol/mol 0.32 - 1.4 2025-10-17 Abnormal redacted 6
Akkermansia Abundance (Stool) [in Stool]
[cb201]

Unit: %  ·  Sample: Stool

Ref Test Name Result Ref Range Date Status Source Page
[b353] Akkermansia 0.008 % 0.02 - 3.0 2024-07-16 Abnormal redacted 1
[b354] Akkermansia 0.038 % 0.02 - 3.0 2024-10-21 Normal redacted 1
Akkermansia muciniphila Count (Stool) [in Stool]
[cb205]

Unit: cfu/g  ·  Sample: Stool

Ref Test Name Result Ref Range Date Status Source Page
[b359] Akkermansia muciniphila 470000000.0 cfu/g 10000000.0 - 500000000.0 2024-11-20 Normal redacted 5
[b360] Akkermansia muciniphila <DL cfu/g (1.00-50.00) 2025-11-25 Abnormal redacted 6
Immunoglobulin E (IgE) [ku/l] [in Serum/Plasma]
[cb2066]

Unit: ku/l  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b3737] Immunoglobulin E (IgE) 404.0 ku/l <= 100.0 2025-07-08 Abnormal redacted 1
[b3738] Immunoglobulin E (IgE) 154.0 ku/l <= 100.0 2026-04-03 Abnormal redacted 10
Inspiratory Vital Capacity [in Respiratory System]
[cb2098]

Unit: l  ·  Sample: Respiratory System

Ref Test Name Result Ref Range Date Status Source Page
[b3818] VC IN 3.99 l >= 4.05 2024-07-15 Abnormal redacted 29
Insulin [uiu/ml] [in Serum/Plasma]
[cb2099]

Unit: uiu/ml  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b3820] Insulin, Serum 6.1 uiu/ml 3.0 - 25.0 2024-09-25 Normal redacted 7
[b3821] Insulin, Serum 14.4 uiu/ml 3.0 - 25.0 2024-12-27 Normal redacted 5
[b3822] Insulin, Serum 15.2 uiu/ml 3.0 - 25.0 2025-03-12 Normal redacted 6
[b3819] Insulin, Serum 17.6 uiu/ml 3.0 - 25.0 2025-05-23 Normal redacted 8
[b3823] Insulin, Serum 28.0 uiu/ml 3.0 - 25.0 2025-06-23 Abnormal redacted 4
[b3824] Insulin, Serum 11.4 uiu/ml 3.0 - 25.0 2025-07-08 Normal redacted 5
[b3825] Insulin, Serum 30.2 uiu/ml 3.0 - 25.0 2025-09-04 Abnormal redacted 4
[b3828] Insulin, Serum 28.3 uiu/ml 3.0 - 25.0 2025-10-17 Abnormal redacted 9
[b3826] Insulin, Serum 137.9 uiu/ml 3.0 - 25.0 2026-01-10 Abnormal redacted 1
[b3827] Insulin, Serum 117.6 uiu/ml 3.0 - 25.0 2026-01-10 Abnormal redacted 1
[b3829] Insulin, Serum 13.6 uiu/ml 3.0 - 25.0 2026-01-10 Normal redacted 4
[b3830] Insulin, Serum 15.2 uiu/ml 3.0 - 25.0 2026-04-03 Normal redacted 8
International Normalized Ratio (INR) [in Whole Blood]
[cb2124]

Unit: ratio  ·  Sample: Whole Blood

Ref Test Name Result Ref Range Date Status Source Page
[b3880] International Normalised Ratio 0.91 ratio 0.8 - 1.15 2024-10-17 Normal redacted 4
[b3881] INR 0.7 ratio 0.9 - 1.2 2024-12-27 Abnormal redacted 2
[b3882] INR 0.7 ratio 0.9 - 1.2 2025-03-12 Abnormal redacted 2
[b3883] INR 0.8 ratio 0.9 - 1.2 2025-05-23 Abnormal redacted 2
[b3884] INR 0.9 ratio 0.9 - 1.2 2025-10-17 Normal redacted 2
[b3885] INR 0.8 ratio 0.9 - 1.2 2025-12-08 Abnormal redacted 2
[b3886] INR 0.9 ratio 0.9 - 1.2 2026-04-03 Normal redacted 2
Kidney Biological Age [in Patient]
[cb2175]

Unit: y  ·  Sample: Patient

Ref Test Name Result Ref Range Date Status Source Page
[b3975] Kidney Biological Age 60.2 y <= 54.4 2025-05-13 Abnormal redacted 7
[b3976] Kidney Biological Age 60.2 y N/A 2025-06-01 - redacted 9
Kidneys Biological Age [in Whole Blood]
[cb2187]

Unit: y  ·  Sample: Whole Blood

Ref Test Name Result Ref Range Date Status Source Page
[b3994] KIDNEYS 60.32 y N/A 2025-02-21 Abnormal redacted 3
LDL Cholesterol [in Serum/Plasma]
[cb2205]

Unit: mmol/l  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b4029] LDL cholesterol 2.0 mmol/l <= 2.6 2024-04-24 Normal redacted 2
[b4027] LDL Cholesterol 2.6 mmol/l <= 2.6 2024-07-15 Normal redacted 8
[b4028] Cholesterol, LDL 1.2 mmol/l <= 2.6 2024-09-25 Normal redacted 5
[b4031] LDL-C 0.96 mmol/l <= 2.6 2024-10-12 Normal redacted 8
[b4030] Cholesterol, LDL 1.5 mmol/l <= 2.6 2024-12-27 Normal redacted 5
[b4033] Cholesterol, LDL 1.5 mmol/l <= 2.6 2025-03-12 Normal redacted 5
[b4032] LDL CHOLESTEROL 1.1 mmol/l <= 2.6 2025-03-15 Normal redacted 4
[b4037] Cholesterol, LDL 1.2 mmol/l <= 2.6 2025-05-23 Normal redacted 7
[b4034] Cholesterol, LDL 1.0 mmol/l <= 2.6 2025-06-23 Normal redacted 4
[b4036] Cholesterol, LDL 1.3 mmol/l <= 2.6 2025-07-08 Normal redacted 4
[b4035] Cholesterol, LDL 1.8 mmol/l <= 2.6 2025-09-04 Normal redacted 4
[b4038] Cholesterol, LDL 1.4 mmol/l <= 2.6 2025-10-17 Normal redacted 8
[b4039] LDL CHOLESTEROL 1.2 mmol/l <= 2.6 2025-11-30 Normal redacted 4
[b4041] Cholesterol, LDL 1.4 mmol/l <= 2.6 2025-12-08 Normal redacted 7
[b4040] Cholesterol, LDL 1.8 mmol/l <= 2.6 2026-01-10 Normal redacted 4
[b4042] Cholesterol, LDL 1.1 mmol/l <= 2.6 2026-04-03 Normal redacted 6
[b4026] Low-Density Lipoprotein (LDL) cholesterol levels Normal mmol/l Low-Normal-High N/A Normal redacted 97
LDL Phenotype Pattern [in Serum/Plasma]
[cb2210]

Unit: N/A  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b4052] LDL Phenotype Pattern TYPE B- ABNORMAL N/A N/A 2024-12-16 - redacted 3
[b4053] LDL Phenotype Pattern TYPE B - ABNORMAL N/A N/A 2026-01-22 Abnormal redacted 3
LDL-3 Cholesterol [in Serum/Plasma]
[cb2213]

Unit: mmol/l  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b4058] Low Density Lipoprotein (LDL-3) 0.21 mmol/l 0.0 - 0.2 2024-12-16 Abnormal redacted 3
[b4059] Low Density Lipoprotein (LDL-3) 0.26 mmol/l 0.0 - 0.2 2026-01-22 Abnormal redacted 3
LDL-4 Cholesterol [in Serum/Plasma]
[cb2214]

Unit: mmol/l  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b4060] Low Density Lipoprotein (LDL-4) 0.05 mmol/l 0.0 - 0.01 2024-12-16 Abnormal redacted 3
[b4061] Low Density Lipoprotein (LDL-4) 0.08 mmol/l 0.0 - 0.01 2026-01-22 Abnormal redacted 3
Lactobacillus species [in Unspecified]
[cb2233]

Unit: N/A  ·  Sample: Unspecified

Ref Test Name Result Ref Range Date Status Source Page
[b4107] Lactobacilli Species Low N/A N/A 2024-12-01 Abnormal redacted 2
[b4108] Lactobacillus species <DL N/A >= 100000.0 2024-12-01 Abnormal redacted 1
Lactobacillus species (Saliva) [in Saliva]
[cb2234]

Unit: N/A  ·  Sample: Saliva

Ref Test Name Result Ref Range Date Status Source Page
[b4109] Lactobacillus species Low N/A N/A 2025-11-17 Abnormal redacted 2
[b4110] Lactobacillus species <DL N/A >= 100000.0 2025-11-17 Abnormal redacted 1
Lactose Degraders (Stool) [in Stool]
[cb2236]

Unit: %  ·  Sample: Stool

Ref Test Name Result Ref Range Date Status Source Page
[b4112] Lactose Degraders 0.25 % >= 0.259 2024-07-16 Abnormal redacted 40
Left Femur Neck Bone Density T-score [in Femur.Neck]
[cb2264]

Unit: N/A  ·  Sample: Femur.Neck

Ref Test Name Result Ref Range Date Status Source Page
[b4149] Left Femur Neck T-score -1.8 N/A > -1.0 2024-07-15 Abnormal redacted 33
Lung Biological Age [in Whole Blood]
[cb2347]

Unit: y  ·  Sample: Whole Blood

Ref Test Name Result Ref Range Date Status Source Page
[b4280] Lung Biological Age 57.9 y <= 54.4 2025-05-13 Abnormal redacted 7
Maximal Expiratory Flow 50% (MEF 50) [in Respiratory System]
[cb2408]

Unit: l/s  ·  Sample: Respiratory System

Ref Test Name Result Ref Range Date Status Source Page
[b4401] MEF 50 4.6 l/s >= 7.38 2024-07-15 Abnormal redacted 29
Maximal Expiratory Flow 75% (MEF 75) [in Respiratory System]
[cb2409]

Unit: l/s  ·  Sample: Respiratory System

Ref Test Name Result Ref Range Date Status Source Page
[b4402] MEF 75 7.49 l/s >= 12.55 2024-07-15 Abnormal redacted 29
Maximal Expiratory Flow at 25% of Forced Vital Capacity (MEF 25) [in Respiratory System]
[cb2410]

Unit: l/s  ·  Sample: Respiratory System

Ref Test Name Result Ref Range Date Status Source Page
[b4403] MEF 25 1.82 l/s >= 2.36 2024-07-15 Abnormal redacted 29
Alpha-2 Globulin [in Serum/Plasma]
[cb246]

Unit: g/l  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b502] Alpha-2 4.2 g/l 5.1 - 8.5 2024-10-12 Abnormal redacted 10
Metabolized Cortisol/Creatinine Ratio [ng/mg] [in Urine]
[cb2478]

Unit: ng/mg  ·  Sample: Urine

Ref Test Name Result Ref Range Date Status Source Page
[b4583] Metabolized Cortisol 2884.0 ng/mg 4550.0 - 10000.0 2026-01-28 Abnormal redacted 1
Microscopic Observation (Inguinal Lymph Node Block) [in Lymph Node.Inguinal]
[cb2500]

Unit: N/A  ·  Sample: Lymph Node.Inguinal

Ref Test Name Result Ref Range Date Status Source Page
[b4625] Inguinal Lymph Block POSITIVE N/A Not Detected 2025-11-05 Abnormal redacted 5
Mitochondrial Efficiency [in Xxx]
[cb2523]

Unit: N/A  ·  Sample: Xxx

Ref Test Name Result Ref Range Date Status Source Page
[b4651] Mitochondrial Efficiency Low N/A Optimal 2025-05-23 Abnormal redacted 6
Mitochondrial Efficiency Score (Percentile) [in Patient]
[cb2524]

Unit: percentile  ·  Sample: Patient

Ref Test Name Result Ref Range Date Status Source Page
[b4652] mescoreTM 46.0 percentile 90.0 - 100.0 2025-06-18 Abnormal redacted 4
Mitochondrial Energy Profile [in Unknown]
[cb2526]

Unit: N/A  ·  Sample: Unknown

Ref Test Name Result Ref Range Date Status Source Page
[b4654] Energy Profile Dysfunction N/A Optimal 2025-05-23 Abnormal redacted 6
Mycoplasma pneumoniae IgA Antibody [in Serum/Plasma]
[cb2618]

Unit: ratio  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b4813] Mycoplasma pneumoniae IgA-AB 1.504 ratio <= 0.8 2025-10-07 Abnormal redacted 5
N-MID Osteocalcin [in Serum/Plasma]
[cb2634]

Unit: ug/l  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b4840] N-MID Osteocalcin 11.0 ug/l 24.0 - 46.0 2024-11-20 Abnormal redacted 1
Nicotinamide Adenine Dinucleotide (NAD+) [in Whole Blood]
[cb2706]

Unit: umol/l  ·  Sample: Whole Blood

Ref Test Name Result Ref Range Date Status Source Page
[b4983] NAD (NAD+) 4.0 umol/l 10.0 - 50.0 2025-01-20 Abnormal redacted 1
[b4984] NAD (NAD+) 15.2 umol/l 20.0 - 42.0 2025-09-22 Abnormal redacted 1
Oxalic Acid/Creatinine Ratio (Urine) [in Urine]
[cb2858]

Unit: mmol/molcr  ·  Sample: Urine

Ref Test Name Result Ref Range Date Status Source Page
[b5202] Oxalic Acid 4.61 mmol/molcr 0.0 - 78.0 2024-12-16 Normal redacted 12
[b5203] Oxalic 173.0 mmol/molcr 8.9 - 67.0 2025-07-29 Abnormal redacted 3
[b5204] Oxalic 54.0 mmol/molcr 8.9 - 67.0 2025-10-17 Normal redacted 6
[b5205] Oxalic Acid 119.29 mmol/molcr 0.0 - 78.0 2026-01-22 Abnormal redacted 12
Pancreatic Elastase (Stool) [in Stool]
[cb2883]

Unit: ug/g  ·  Sample: Stool

Ref Test Name Result Ref Range Date Status Source Page
[b5265] Pancreatic Elastase 209.0 ug/g >= 200.0 2024-11-20 Normal redacted 1
[b5266] Pancreatic Elastase 85.0 ug/g >= 200.0 2025-11-07 Abnormal redacted 2
[b5267] Pancreatic Elastase Normal ug/g >= 200.0 2025-12-03 Normal redacted 12
Parvimonas micra [in Xxx]
[cb2905]

Unit: N/A  ·  Sample: Xxx

Ref Test Name Result Ref Range Date Status Source Page
[b5302] Parvmonas Micra Elevated N/A N/A 2024-12-01 Abnormal redacted 2
[b5303] Parvimonas micra 7130000.0 N/A <= 4000000.0 2024-12-01 Abnormal redacted 1
Peak Expiratory Flow (PEF) [in Respiratory System]
[cb2920]

Unit: l/s  ·  Sample: Respiratory System

Ref Test Name Result Ref Range Date Status Source Page
[b5331] PEF 8.55 l/s >= 13.36 2024-07-15 Abnormal redacted 29
Peak Methane (Breath) [in Breath]
[cb2921]

Unit: ppm  ·  Sample: Breath

Ref Test Name Result Ref Range Date Status Source Page
[b5332] Methane (CH4) Peak 27.0 ppm <= 10.0 2026-01-02 Abnormal redacted 1
Peak Methane (Exhaled Gas) [in Exhaled Gas]
[cb2922]

Unit: ppm  ·  Sample: Exhaled Gas

Ref Test Name Result Ref Range Date Status Source Page
[b5333] Peak methane level at any point 16.0 ppm <= 10.0 2025-11-17 Abnormal redacted 1
Proinsulin [in Serum/Plasma]
[cb3086]

Unit: pmol/l  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b5629] Proinsulin 76.0 pmol/l 3.6 - 22.0 2026-01-10 Abnormal redacted 1
[b5628] Proinsulin 21.0 pmol/l 3.6 - 22.0 2026-01-19 Normal redacted 1
[b5630] Proinsulin 141.0 pmol/l 3.6 - 22.0 2026-01-19 Abnormal redacted 3
Prostate Gland Volume [in Prostate Gland]
[cb3099]

Unit: N/A  ·  Sample: Prostate Gland

Ref Test Name Result Ref Range Date Status Source Page
[b5657] Prostate Gland Size Normal N/A N/A 2024-07-15 Normal redacted 31
Prostate Health Index (PHI) [in Serum/Plasma]
[cb3100]

Unit: N/A  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b5658] phi 106 N/A N/A 2024-11-08 - redacted 1
[b5659] phi 106.11 N/A N/A 2024-11-08 Abnormal redacted 1
Prostate Specific Antigen (PSA) [in Serum/Plasma]
[cb3103]

Unit: ug/l  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b5665] PSA 0.77 ug/l 0.0 - 4.0 2024-07-15 Normal redacted 11
[b5664] PROSTATE SPECIFIC ANTIGEN 0.71 ug/l <= 3.5 2024-10-12 Normal redacted 7
[b5663] Total PSA 0.81 ug/l 0.0 - 4.0 2024-11-08 Normal redacted 1
[b5662] Prostate Specific Antigen (PSA) 0.64 ug/l 0.0 - 4.0 2024-11-22 Normal redacted 1
Prostate Suspicion Criteria Met [in ^Patient]
[cb3104]

Unit: count  ·  Sample: ^Patient

Ref Test Name Result Ref Range Date Status Source Page
[b5666] Prostate Suspicion Criteria Met 5.0 count 0.0 - 4.0 2025-11-05 Abnormal redacted 5
Proteobacteria (Stool) [in Stool]
[cb3113]

Unit: %  ·  Sample: Stool

Ref Test Name Result Ref Range Date Status Source Page
[b5676] Proteobacteria 11.376 % 0.0 - 4.0 2024-07-16 Abnormal redacted 17
[b5677] Proteobacteria 7.766 % 0.0 - 4.0 2024-10-21 Abnormal redacted 17
[b5675] Proteobacteria Phylum 2.214 % 0.05 - 12.5 2024-11-20 Normal redacted 6
[b5678] Proteobacteria Phylum 0.291 % 0.25 - 5.0 2025-11-25 Normal redacted 7
Pseudomonas aeruginosa (Saliva) [in Saliva]
[cb3125]

Unit: cfu/ml  ·  Sample: Saliva

Ref Test Name Result Ref Range Date Status Source Page
[b5699] Pseudomonas aeruginosa 62720000.0 cfu/ml <= 1000000.0 2025-11-17 Abnormal redacted 1
Rheumatoid Factor [in Serum/Plasma]
[cb3223]

Unit: iu/ml  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b5881] Rheumatoid Factor 28.0 iu/ml <= 20.0 2024-05-14 Abnormal redacted 1
[b5887] Rheumatoid Factor 23.0 iu/ml <= 20.0 2024-07-15 Abnormal redacted 10
[b5880] Rheumatoid Factor 27.6 iu/ml <= 14.0 2024-09-25 Abnormal redacted 8
[b5883] Rheumatoid Factor 29.0 iu/ml <= 20.0 2024-10-12 Abnormal redacted 9
[b5884] Rheumatoid Factor 29.4 iu/ml <= 14.0 2024-12-27 Abnormal redacted 7
[b5885] Rheumatoid Factor 21.0 iu/ml <= 14.0 2025-03-12 Abnormal redacted 7
[b5882] RHEUMATOID FACTOR 24.0 iu/ml <= 14.0 2025-03-15 Abnormal redacted 7
[b5879] Rheumatoid Factor 19.9 iu/ml <= 14.0 2025-05-23 Abnormal redacted 10
[b5886] Rheumatoid Factor 22.7 iu/ml <= 14.0 2025-10-17 Abnormal redacted 10
[b5888] Rheumatoid Factor 18.0 iu/ml <= 14.0 2025-11-30 Abnormal redacted 7
[b5889] Rheumatoid Factor 19.7 iu/ml <= 14.0 2025-12-08 Abnormal redacted 7
[b5890] Rheumatoid Factor 15.3 iu/ml <= 14.0 2026-04-03 Abnormal redacted 9
Roseburia [in Stool]
[cb3257]

Unit: %  ·  Sample: Stool

Ref Test Name Result Ref Range Date Status Source Page
[b5935] Roseburia 1.55 % 5.0 - 11.0 2024-07-16 Abnormal redacted 7
[b5936] Roseburia 2.608 % 5.0 - 11.0 2024-10-21 Abnormal redacted 7
Schistosoma sp IgG (EIA) [in Serum/Plasma]
[cb3307]

Unit: index  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b6018] Schistosoma-spp.-AB IgG (EIA) 2.2 index <= 0.8 2025-12-06 Abnormal redacted 2
Secretory Immunoglobulin A (Saliva) [in Saliva]
[cb3316]

Unit: mg/l  ·  Sample: Saliva

Ref Test Name Result Ref Range Date Status Source Page
[b6029] Secretory IgA 50.0 mg/l 102.0 - 471.0 2024-05-11 Abnormal redacted 1
Sinus Block/Inflammation/Dysfunction [in Sinuses]
[cb3365]

Unit: N/A  ·  Sample: Sinuses

Ref Test Name Result Ref Range Date Status Source Page
[b6132] Sinus Block/Inflammation/Dysfunction Severe N/A N/A 2025-05-11 Abnormal redacted 3
Streptococcus salivarius [in Unspecified]
[cb3461]

Unit: N/A  ·  Sample: Unspecified

Ref Test Name Result Ref Range Date Status Source Page
[b6322] Streptococcus salivarius <DL N/A >= 50000000.0 2024-12-01 Abnormal redacted 1
[b6323] Streptococcus Salivarius Low N/A N/A 2024-12-01 Abnormal redacted 2
Streptococcus salivarius (Saliva) [in Saliva]
[cb3462]

Unit: N/A  ·  Sample: Saliva

Ref Test Name Result Ref Range Date Status Source Page
[b6325] Streptococcus salivarius POSITIVE N/A N/A 2024-10-23 - redacted 8
[b6324] Streptococcus salivarius <DL N/A >= 50000000.0 2025-11-17 Abnormal redacted 1
[b6326] Streptococcus salivarius Low N/A N/A 2025-11-17 Abnormal redacted 2
Suspect for Hypertrophic Change Event [in Heart]
[cb3512]

Unit: N/A  ·  Sample: Heart

Ref Test Name Result Ref Range Date Status Source Page
[b6397] Suspect For Hypertrophic Change Event Severe N/A Optimal 2025-11-05 Abnormal redacted 5
Systolic Blood Pressure (Night) [in Arterial System]
[cb3530]

Unit: mmhg  ·  Sample: Arterial System

Ref Test Name Result Ref Range Date Status Source Page
[b6473] Systolic Blood Pressure (Night-time) 110.0 mmhg 105.0 - 120.0 2025-09-01 Normal redacted 1
[b6474] Systolic Blood Pressure (Night-time) 128.0 mmhg 105.0 - 120.0 2025-09-01 Abnormal redacted 1
[b6475] Systolic Blood Pressure (Night-time) 100.0 mmhg 105.0 - 120.0 2025-09-01 Abnormal redacted 1
T-Score (AP Spine L1) [in Spine.L1]
[cb3538]

Unit: N/A  ·  Sample: Spine.L1

Ref Test Name Result Ref Range Date Status Source Page
[b6487] AP Spine L1 T-score -1.4 N/A > -1.0 2024-07-15 Abnormal redacted 33
T-score (Hip) [in Hip]
[cb3540]

Unit: N/A  ·  Sample: Hip

Ref Test Name Result Ref Range Date Status Source Page
[b6489] T-score (Hip) -1.3 N/A N/A 2024-07-15 Abnormal redacted 32
Testosterone [in Serum/Plasma]
[cb3586]

Unit: nmol/l  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b6555] Testosterone 15.6 nmol/l 8.0 - 31.3 2024-09-25 Normal redacted 7
[b6557] Testosterone 16.2 nmol/l 6.7 - 25.7 2024-12-16 Normal redacted 5
[b6556] Testosterone 17.9 nmol/l 8.0 - 31.3 2024-12-27 Normal redacted 6
[b6558] Testosterone 12.1 nmol/l 8.0 - 31.3 2025-03-12 Normal redacted 7
[b6562] Testosterone 19.5 nmol/l 8.0 - 31.3 2025-05-23 Normal redacted 9
[b6559] Testosterone 19.7 nmol/l 8.0 - 31.3 2025-06-23 Normal redacted 5
[b6560] Testosterone 21.4 nmol/l 8.0 - 31.3 2025-07-08 Normal redacted 5
[b6561] Testosterone 17.5 nmol/l 8.0 - 31.3 2025-09-04 Normal redacted 5
[b6563] Testosterone 16.2 nmol/l 8.0 - 31.3 2025-10-17 Normal redacted 10
[b6564] Testosterone 14.9 nmol/l 6.5 - 23.7 2026-01-10 Normal redacted 5
[b6565] Testosterone 11.7 nmol/l 6.7 - 25.7 2026-01-22 Normal redacted 5
[b6566] Testosterone 19.3 nmol/l 6.5 - 23.7 2026-04-03 Normal redacted 8
Thyroid Stimulating Hormone (TSH) [in Serum/Plasma]
[cb3616]

Unit: miu/l  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b6629] TSH 3.77 miu/l 0.5 - 5.0 2024-05-14 Normal redacted 2
[b6642] TSH 4.59 miu/l 0.27 - 4.2 2024-07-15 Abnormal redacted 10
[b6630] Thyroid Stimulating Hormone 3.07 miu/l 0.35 - 4.55 2024-09-25 Normal redacted 6
[b6631] TSH 3.16 miu/l 0.5 - 5.0 2024-09-25 Normal redacted 1
[b6635] Thyroid Stimulating Hormone 3.76 miu/l 0.4 - 4.7 2024-10-12 Normal redacted 3
[b6638] TSH 3.5 miu/l 0.5 - 5.0 2024-12-16 Normal redacted 5
[b6632] Thyroid Stimulating Hormone 2.38 miu/l 0.35 - 4.55 2024-12-27 Normal redacted 5
[b6636] Thyroid Stimulating Hormone 3.2 miu/l 0.35 - 4.55 2025-03-12 Normal redacted 5
[b6633] TSH 1.42 miu/l 0.55 - 4.78 2025-03-15 Normal redacted 6
[b6628] Thyroid Stimulating Hormone 3.52 miu/l 0.35 - 4.55 2025-05-23 Normal redacted 8
[b6637] Thyroid Stimulating Hormone 2.39 miu/l 0.35 - 4.55 2025-06-23 Normal redacted 4
[b6634] Thyroid Stimulating Hormone 2.17 miu/l 0.35 - 4.55 2025-07-08 Normal redacted 4
[b6639] Thyroid Stimulating Hormone 2.07 miu/l 0.35 - 4.55 2025-09-04 Normal redacted 4
[b6640] Thyroid Stimulating Hormone 2.62 miu/l 0.35 - 4.55 2025-10-17 Normal redacted 9
[b6641] TSH 1.95 miu/l 0.55 - 4.78 2025-11-30 Normal redacted 6
[b6644] Thyroid Stimulating Hormone 2.07 miu/l 0.35 - 4.55 2025-12-08 Normal redacted 7
[b6643] Thyroid Stimulating Hormone 2.1 miu/l 0.35 - 4.55 2026-01-10 Normal redacted 4
[b6645] TSH 2.62 miu/l 0.4 - 4.0 2026-01-22 Normal redacted 5
[b6646] Thyroid Stimulating Hormone 2.09 miu/l 0.35 - 4.55 2026-04-03 Normal redacted 7
Triglycerides [in Serum/Plasma]
[cb3743]

Unit: mmol/l  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b6916] Triglycerides 1.5 mmol/l <= 1.71 2024-04-24 Normal redacted 2
[b6929] Triglycerides 1.1 mmol/l <= 1.7 2024-07-15 Normal redacted 8
[b6915] Triglycerides 0.9 mmol/l <= 1.7 2024-09-25 Normal redacted 5
[b6917] Triglyceride 1.05 mmol/l <= 1.7 2024-10-12 Normal redacted 8
[b6922] Triglycerides 2.0 mmol/l 0.0 - 2.0 2024-12-16 Normal redacted 3
[b6919] Triglycerides 2.2 mmol/l <= 1.7 2024-12-27 Abnormal redacted 5
[b6920] Triglycerides 1.3 mmol/l <= 1.7 2025-03-12 Normal redacted 5
[b6918] TRIGLYCERIDES 2.9 mmol/l <= 1.7 2025-03-15 Abnormal redacted 4
[b6925] Triglycerides 1.7 mmol/l <= 1.7 2025-05-23 Normal redacted 7
[b6921] Triglycerides 1.7 mmol/l <= 1.7 2025-06-23 Normal redacted 4
[b6924] Triglycerides 2.1 mmol/l <= 1.7 2025-07-08 Abnormal redacted 4
[b6923] Triglycerides 1.6 mmol/l <= 1.7 2025-09-04 Normal redacted 4
[b6926] Triglycerides 2.0 mmol/l <= 1.7 2025-10-17 Abnormal redacted 5
[b6930] TRIGLYCERIDES 1.1 mmol/l <= 1.7 2025-11-30 Normal redacted 4
[b6932] Triglycerides 1.2 mmol/l <= 1.7 2025-12-08 Normal redacted 7
[b6927] Triglycerides 2.4 mmol/l <= 2.0 2026-01-10 Abnormal redacted 1
[b6928] Triglycerides 2.3 mmol/l <= 1.7 2026-01-10 Abnormal redacted 1
[b6931] Triglycerides 2.2 mmol/l <= 1.7 2026-01-10 Abnormal redacted 4
[b6933] Triglycerides 1.1 mmol/l 0.0 - 2.0 2026-01-22 Normal redacted 3
[b6934] Triglycerides 1.0 mmol/l <= 1.7 2026-04-03 Normal redacted 6
[b6914] Triglycerides levels Normal mmol/l Low-Normal-High N/A Normal redacted 97
Urine Protein (Qualitative) [in Urine]
[cb3828]

Unit: N/A  ·  Sample: Urine

Ref Test Name Result Ref Range Date Status Source Page
[b7214] Protein, urine Negative N/A Negative 2024-04-24 Normal redacted 3
[b7223] Protein Negative N/A N/A 2024-07-15 Normal redacted 12
[b7213] Urine Protein Trace N/A N/A 2024-09-25 Abnormal redacted 10
[b7216] Protein NEGATIVE N/A Nil 2024-10-12 Normal redacted 6
[b7218] Urine Protein Negative N/A Negative 2024-12-27 Normal redacted 10
[b7219] Urine Protein Negative N/A N/A 2025-03-12 Normal redacted 9
[b7217] Protein Negative N/A N/A 2025-03-15 Normal redacted 7
[b7211] Urine Protein Negative N/A N/A 2025-05-23 Normal redacted 16
[b7215] Urine Protein NN N/A N/A 2025-06-23 - redacted 7
[b7220] Urine Protein Negative N/A Negative 2025-07-08 Normal redacted 8
[b7221] Urine Protein Negative N/A N/A 2025-09-04 Normal redacted 7
[b7222] Urine Protein Negative N/A N/A 2025-10-17 Normal redacted 12
[b7212] Protein Negative N/A N/A 2025-11-30 Normal redacted 8
[b7225] Urine Protein Negative N/A N/A 2025-12-08 Normal redacted 8
[b7224] Urine Protein Negative N/A N/A 2026-01-10 Normal redacted 7
[b7226] Urine Protein Negative N/A N/A 2026-04-03 Normal redacted 12
VLDL Cholesterol [in Serum/Plasma]
[cb3837]

Unit: mmol/l  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b7264] Very Low Density Lipoprotein (VLDL) 0.7 mmol/l 0.1 - 0.6 2024-12-16 Abnormal redacted 3
[b7265] Very Low Density Lipoprotein (VLDL) 0.6 mmol/l 0.1 - 0.6 2026-01-22 Normal redacted 3
Von Willebrand Factor Antigen [in Serum/Plasma]
[cb3918]

Unit: %  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b7390] vWF:Ag 189.6 % 50.0 - 150.0 2025-09-01 Abnormal redacted 5
Von Willebrand Factor Ristocetin Cofactor Activity [in Serum/Plasma]
[cb3919]

Unit: %  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b7391] vWF:Activity(RiCoF) 155.1 % 50.0 - 150.0 2025-09-01 Abnormal redacted 5
Young Adult T-score (Left Femur Total) [in Femur.Left]
[cb3964]

Unit: N/A  ·  Sample: Femur.Left

Ref Test Name Result Ref Range Date Status Source Page
[b7468] Left Femur Total T-score -1.3 N/A > -1.0 2024-07-15 Abnormal redacted 33
Beta-CrossLaps (Beta-CTx) [in Serum/Plasma]
[cb590]

Unit: ng/l  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b1063] Beta X Laps 90.0 ng/l 161.0 - 737.0 2024-11-20 Abnormal redacted 1
[b1064] B-CrossLaps(B-CTx) 50.0 ng/l 10.0 - 710.0 2025-10-17 Normal redacted 11
[b1065] Beta-CrossLaps 137.0 ng/l <= 704.0 2025-11-30 Normal redacted 7
Beta-Tetrahydrocortisol (Urine) [in Urine]
[cb598]

Unit: ug/g  ·  Sample: Urine

Ref Test Name Result Ref Range Date Status Source Page
[b1080] b-Tetrahydrocortisol (b-THF) 1235.0 ug/g 1750.0 - 4000.0 2026-01-28 Abnormal redacted 5
Bifidobacterium (Stool) [in Stool]
[cb602]

Unit: %  ·  Sample: Stool

Ref Test Name Result Ref Range Date Status Source Page
[b1087] Bifidobacterium 0.041 % 2.5 - 5.0 2024-07-16 Abnormal redacted 3
[b1086] Bifidobacterium 0.037 % 2.5 - 5.0 2024-10-21 Abnormal redacted 3
Bifidobacterium bifidum (Stool) [in Stool]
[cb605]

Unit: N/A  ·  Sample: Stool

Ref Test Name Result Ref Range Date Status Source Page
[b1093] Bifidobacterium bifidum Low N/A N/A 2024-11-20 Abnormal redacted 14
Brain System Age [in ^Patient]
[cb785]

Unit: y  ·  Sample: ^Patient

Ref Test Name Result Ref Range Date Status Source Page
[b1362] Brain System Age 53.0 y >= 54.7 2025-08-19 Abnormal redacted 4
C-Peptide [in Serum/Plasma]
[cb837]

Unit: nmol/l  ·  Sample: Serum/Plasma

Ref Test Name Result Ref Range Date Status Source Page
[b1428] C-peptide, Serum 2.37 nmol/l 0.27 - 1.28 2026-01-10 Abnormal redacted 1
[b1429] C-peptide, Serum 2.55 nmol/l 0.27 - 1.28 2026-01-10 Abnormal redacted 1
[b1430] C-peptide, Serum 0.94 nmol/l 0.27 - 1.28 2026-01-10 Normal redacted 5
CD3+CD8+CD28- Cells Count [in Whole Blood]
[cb849]

Unit: cells/ul  ·  Sample: Whole Blood

Ref Test Name Result Ref Range Date Status Source Page
[b1454] CD8+/CD28- in CD3 (CD3+CD8+CD28-) 417.0 cells/ul 11.0 - 359.0 2025-07-21 Abnormal redacted 2
CD4/CD8 Ratio [in Whole Blood]
[cb858]

Unit: ratio  ·  Sample: Whole Blood

Ref Test Name Result Ref Range Date Status Source Page
[b1467] CD4/CD8 ratio (T Cells) 0.9 ratio 0.9 - 2.5 2025-01-09 Normal redacted 6
[b1468] CD4/CD8 ratio (T Cells) 0.86 ratio 0.9 - 2.5 2025-07-08 Abnormal redacted 2
[b1469] Ratio (CD4:CD8) 0.86 ratio 0.96 - 3.93 2025-07-21 Abnormal redacted 2
[b1470] CD4T/CD8T Ratio 7.1 ratio 1.0 - 4.0 2025-08-19 Abnormal redacted 7
[b1471] CD4/CD8 ratio (T Cells) 1.0 ratio 0.9 - 2.5 2025-11-19 Normal redacted 1
CD57+ Natural Killer Cells [in Whole Blood]
[cb860]

Unit: cells/ul  ·  Sample: Whole Blood

Ref Test Name Result Ref Range Date Status Source Page
[b1475] CD57+ NK-cells (absolute) 70.0 cells/ul 100.0 - 360.0 2025-12-06 Abnormal redacted 2
[b1476] CD57+ NK-cells (%) 54.33 cells/ul 2.0 - 77.0 2025-12-06 Normal redacted 2
CD8+CD28- Cells [in Whole Blood]
[cb865]

Unit: cells/ul  ·  Sample: Whole Blood

Ref Test Name Result Ref Range Date Status Source Page
[b1485] CD8+/CD28- in CD8 (CD8+CD28-) 397.0 cells/ul 17.0 - 364.0 2025-07-21 Abnormal redacted 2
CD8+CD28- Cells/100 CD8+ Cells [in Whole Blood]
[cb866]

Unit: %  ·  Sample: Whole Blood

Ref Test Name Result Ref Range Date Status Source Page
[b1486] CD8+/CD28- in CD8 (CD8+CD28-) 58.0 % 4.0 - 51.0 2025-07-21 Abnormal redacted 2
CD8+CD95- Cells (% of CD8+ Cells) [in Whole Blood]
[cb869]

Unit: %  ·  Sample: Whole Blood

Ref Test Name Result Ref Range Date Status Source Page
[b1489] CD8+/CD95- in CD8 (CD8+CD95-) 10.0 % 11.0 - 57.0 2025-07-21 Abnormal redacted 2
Campylobacter rectus [in Unspecified]
[cb903]

Unit: cfu/ml  ·  Sample: Unspecified

Ref Test Name Result Ref Range Date Status Source Page
[b1566] Campylobacter rectus 1830000.0 cfu/ml <= 1000000.0 2024-12-01 Abnormal redacted 1
Other Tests

Individual tests cited in the body that are not part of any biomarker group.

Ref Test Name Result Ref Range Date Status Source Page
[b3499] Hep.A antibody (IgG)-anti-HAV POSITIVE Negative 2024-10-12 Abnormal redacted 7
[b2278] Dengue IgG Positive Negative 2024-12-27 Abnormal redacted 8
[b2279] Dengue IgM Positive Negative 2024-12-27 Abnormal redacted 8
[b2604] OMICm Age 57.9 <= 54.4 2025-05-13 Abnormal redacted 2
[b3718] Immune Biological Age 59.0 <= 54.4 2025-05-13 Abnormal redacted 7
[b2937] Free Cortisol (1st Morning) 51.14 7.8 - 29.5 2025-07-21 Abnormal redacted 1
[b2939] Free Cortisol (2nd Morning) 94.69 23.4 - 68.9 2025-07-21 Abnormal redacted 1
[b3525] HSV-1/2 IgG-Ab (Elisa) 31.92 0.0 - 20.0 2025-07-22 Abnormal redacted 6
[b3630] Hormone System Age 61.8 <= 54.7 2025-08-19 Abnormal redacted 4
[b2634] EBV VCA p23 IgG Positive Negative 2025-10-07 Abnormal redacted 5
[b2635] EBV VCA p18 IgG Positive Negative 2025-10-07 Abnormal redacted 5
[b3635] HHV-6-AB IgG (IFT) 1:320 < 1:10 2025-10-07 Abnormal redacted 1
[b6859] Toxoplasma gondii IgG-AB 2.129 <= 0.8 2025-10-07 Abnormal redacted 5
[b3163] Glucose 6.3 3.9 - 6.0 2026-01-10 Abnormal redacted 1
[b2938] Free Cortisol (1st Morning) 36.78 7.8 - 29.5 2026-01-29 Abnormal redacted 1
[b2940] Free Cortisol (2nd Morning) 32.65 23.4 - 68.9 2026-01-29 Normal redacted 1
[b7360] Vitamin B12 766.0 156.0 - 672.0 2026-04-03 Abnormal redacted 11

A2. Diagnoses

Ref Name Status First Documented Source Page
[d5] plantar fibroma Chronic 2015-09-15 redacted 1
[d79] Hypertension Chronic 2022-07-15 redacted 1
[d1] Excessive Overload of Left Atrium Undetermined 2024-04-14 redacted 1
[d6] Adrenal insufficiency Chronic 2024-05-11 redacted 2
[d71] Mild hyperlipidemia Chronic 2024-07-15 redacted 7
[d72] Right maxillary lesion and uvulal deflection Acute 2024-07-15 redacted 7
[d73] Diabetes Chronic 2024-07-15 redacted 1
[d74] Mild atherosclerotic coronary plaque deposits Chronic 2024-07-15 redacted 7
[d75] Gallbladder polyps Chronic 2024-07-15 redacted 5
[d76] Osteopenia Chronic 2024-07-15 redacted 1
[d77] Fatty Liver with focal sparing Chronic 2024-07-15 redacted 31
[d78] Cholelithiasis Chronic 2024-07-15 redacted 7
[d10] ACUTE GASTRITIS Acute 2024-07-19 redacted 1
[d9] COLITIS Acute 2024-07-19 redacted 1
[d0] Gallbladder polyp Undetermined 2024-10-12 redacted 3
[d12] Cholelithiasis Chronic 2024-10-12 redacted 4
[d13] Tiny gallbladder polyps Chronic 2024-10-12 redacted 4
[d14] Fatty liver with focal fatty sparing Chronic 2024-10-12 redacted 4
[d84] Hereditary chronic pancreatitis Chronic 2024-10-17 redacted 14
[d85] Autosomal recessive mental retardation type 5 Chronic 2024-10-17 redacted 23
[d2] Low Lactobacilli Species Undetermined 2024-12-01 redacted 2
[d3] Elevated Parvmonas Micra Undetermined 2024-12-01 redacted 2
[d4] Low Streptococcus Salivarius Undetermined 2024-12-01 redacted 2
[d7] Elevated Campylobacter Rectus Undetermined 2024-12-01 redacted 2
[d80] Refractory Periodontitis Chronic 2024-12-04 redacted 2
[d11] Bilateral small hydroceles Chronic 2024-12-10 redacted 2
[d50] Prediabetes Chronic 2025-03-15 redacted 2
[d15] Infraspinatus partial tearing Chronic 2025-04-05 redacted 1
[d16] Mild acromioclavicular arthropathy Chronic 2025-04-05 redacted 2
[d20] Subacromial subdeltoid bursitis Undetermined 2025-04-05 redacted 1
[d21] Supraspinatus tendinosis with partial thickness tear Chronic 2025-04-05 redacted 1
[d22] Small thin subscapularis intrasubstance fissure Undetermined 2025-04-05 redacted 2
[d23] Left Ventricular Hypertrophy Undetermined 2025-04-05 redacted 2
[d24] Degenerative changes involving the lateral cuneiform bone Chronic 2025-04-05 redacted 2
[d25] Focal subcortical pain bone marrow edema at the distal tibia anteriorly Chronic 2025-04-05 redacted 2
[d26] Reduced cervical lordosis Chronic 2025-04-05 redacted 1
[d27] Left subacromial subdeltoid bursitis Chronic 2025-04-05 redacted 1
[d28] Right subacromial subdeltoid bursitis Chronic 2025-04-05 redacted 1
[d29] Focal fissuring of the anterosuperior labrum Undetermined 2025-04-05 redacted 1
[d30] Mild supraspinatus tendinosis Undetermined 2025-04-05 redacted 1
[d31] Mild subacromial subdeltoid bursitis Undetermined 2025-04-05 redacted 1
[d32] Mild right acromioclavicular arthropathy Chronic 2025-04-05 redacted 1
[d33] Mild left supraspinatus tendinosis Chronic 2025-04-05 redacted 1
[d34] Right infraspinatus partial tear Chronic 2025-04-05 redacted 1
[d35] Cervical disc bulge at C5/6 and C6/7 Chronic 2025-04-05 redacted 1
[d36] Right supraspinatus tendinosis/partial thickness tear Chronic 2025-04-05 redacted 1
[d37] Mild straightening of the usual cervical lordosis Chronic 2025-04-05 redacted 3
[d38] Mild thinning of the medial femorotibial articular cartilage Chronic 2025-04-05 redacted 1
[d39] Trabeculated bladder wall Chronic 2025-04-05 redacted 3
[d40] Mild increased intrasubstance signal within the posterior horn of the medial meniscus, without definite tear Chronic 2025-04-05 redacted 1
[d41] Lumbosacral transitional vertebral anomaly Chronic 2025-04-05 redacted 3
[d42] Disc bulges at C5-C6, C6-C7 and L2-L3 Chronic 2025-04-05 redacted 3
[d43] Bladder diverticulum Chronic 2025-04-05 redacted 2
[d44] Small umbilical hernia containing fat Chronic 2025-04-05 redacted 3
[d45] Lesion in T1 vertebral body, likely a hemangioma Chronic 2025-04-05 redacted 3
[d46] Paradoxical middle turbinates Chronic 2025-04-05 redacted 3
[d47] S-shaped nasal septal deviation Chronic 2025-04-05 redacted 3
[d48] Turbinates hypertrophy Chronic 2025-04-05 redacted 3
[d49] L5-S1 disc dehydration Chronic 2025-04-05 redacted 3
[d8] Focal fissure of the anterosuperior labrum Undetermined 2025-04-05 redacted 1
[d17] Thin Baker's cyst Chronic 2025-05-04 redacted 1
[d18] Chondromalacia grade 4 of the medial patellar cartilage Chronic 2025-05-04 redacted 1
[d19] Mild degenerative signal of the medial meniscus Chronic 2025-05-04 redacted 1
[d51] Low Mitochondrial Efficiency Chronic 2025-05-23 redacted 4
[d54] Testosterone deficiencies Chronic 2025-05-23 redacted 21
[d70] Chronic high cortisol Chronic 2025-07-21 redacted 8
[d55] Recent Coxsackie-Virus Type A7 and B1 infection Acute 2025-07-22 redacted 8
[d57] Chronic immune-suppression Chronic 2025-07-22 redacted 2
[d58] Schistosomiasis (bilharzia) Undetermined 2025-07-22 redacted 2
[d52] Chlamydia pneumoniae infection Acute 2025-08-21 redacted 2
[d56] Mycoplasma pneumoniae infection Acute 2025-10-07 redacted 5
[d53] Mild Meibomian Gland Dysfunction Chronic 2025-10-24 redacted 1
[d59] pancreatic insufficiency Undetermined 2025-11-18 redacted 2
[d60] Multiple tiny simple liver cysts Undetermined 2025-11-27 redacted 1
[d61] Cervical spondylosis Chronic 2025-11-27 redacted 1
[d62] C4-5 posterior disc prolapse that abuts and possibly impinges the right C5 exiting nerve root Undetermined 2025-11-27 redacted 1
[d63] C5-6 posterior disc prolapse that abuts the right C6 exiting nerve root Undetermined 2025-11-27 redacted 2
[d64] C3-4 and C6-7 posterior disc prolapse Undetermined 2025-11-27 redacted 1
[d65] T1 vertebral hemangioma Chronic 2025-11-27 redacted 2
[d66] Partial tear of the supraspinatus tendon Undetermined 2025-11-27 redacted 1
[d67] Methane-Positive Small Intestinal Bacterial Overgrowth (SIBO) Undetermined 2026-01-02 redacted 1
[d68] Impaired fasting glucose Chronic 2026-01-10 redacted 1
[d69] Diabetes Mellitus Undetermined 2026-01-10 redacted 1
[d81] Tannerella forsythia Chronic 2026-01-26 redacted 8
[d82] Aggregatibacter actinomycetemcomitans in the oral cavity Chronic 2026-01-26 redacted 6
[d83] Advanced periodontitis due to Treponema denticola Chronic 2026-01-26 redacted 11

A3. Procedures

Ref Name Date Source Page
[p1] LASIK surgery 1995-12-01 redacted 1
[p0] Haemorrhoidectomy 2024-07-15 redacted 1

A4. Medications & Supplements

Ref Name Dose Frequency Started Stopped Source Page
[m2] Atorvastatin (Atozet) 10 mg once daily 2024-07-15 - redacted 7
[m4] Hydrochlorothiazide (HCT) 25 mg daily 2024-07-15 - redacted 2
[m5] Irbesartan (Aprovel) 150 mg daily 2024-07-15 - redacted 2
[m6] Ezetimibe (Atozet) 20 mg once daily 2024-07-15 - redacted 7
[m66] Nicotinamide Riboside 300 mg every morning 2024-12-27 - redacted 18
[m67] Spermidine 1 mg daily 2024-12-27 - redacted 18
[m0] Vitamin D 25 mcg as directed 2025-07-21 - redacted 2
[m10] Chromium 100 mcg as directed 2026-01-11 - redacted 13
[m11] 1-MNA 50 mg as directed 2026-01-11 - redacted 4
[m12] Alpha Lipoic Acid 300 mg daily 2026-01-11 - redacted 6
[m13] Fish Oil 2 g as directed 2026-01-11 - redacted 5
[m15] B Complex (Doctor’s Best Fully Active B complex) 300 mg as directed 2026-01-11 - redacted 3
[m16] Molybdenum 75 mcg as directed 2026-01-11 - redacted 15
[m17] Pancrelipase (Creon) 30000 units with meals 2026-01-11 - redacted 1
[m18] Iodine (Potassium Iodide) 150 mcg as directed 2026-01-11 - redacted 8
[m19] Bergamot Orange 500 mg every evening 2026-01-11 - redacted 12
[m20] L-Theanine 200 mg as directed 2026-01-11 - redacted 14
[m21] Metformin (Diabetmin XR 500) 500 mg twice daily 2026-01-11 - redacted 3
[m22] Tauroursodeoxycholic Acid (TUDCA) 500 mg as directed 2026-01-11 - redacted 11
[m23] Silymarin (Milk Thistle) 150 mg twice daily 2026-01-11 - redacted 8
[m24] Vitamin B12 750 mcg as directed 2026-01-11 - redacted 4
[m25] Astaxanthin 8 mg daily 2026-01-11 - redacted 6
[m26] Saffron Extract 15 mg as directed 2026-01-11 - redacted 16
[m27] Lobeglitazone 0.25 mg as directed 2026-01-11 - redacted 3
[m28] Mitoquinol Mesylate (MitoQ) 20 mg as directed 2026-01-11 - redacted 10
[m29] Lutein 10 mg as directed 2026-01-11 - redacted 14
[m30] Atorvastatin (Atozet) 20 mg daily 2026-01-11 - redacted 3
[m31] DHEA (Douglas Laboratories) 10 mg as directed 2026-01-11 - redacted 5
[m33] Proanthocyanidins (Pine Bark Extract) 100 mg twice daily 2026-01-11 - redacted 8
[m34] L-Taurine 750 mg twice daily 2026-01-11 - redacted 7
[m35] L-Glycine 3 g daily at bedtime 2026-01-11 - redacted 10
[m36] Vitamin K2 120 mcg as directed 2026-01-11 - redacted 16
[m37] Urolithin A (Mitopure) 500 mg as directed 2026-01-11 - redacted 4
[m38] Phosphatidylserine 200 mg daily 2026-01-11 - redacted 11
[m39] Zeaxanthin 2 mg as directed 2026-01-11 - redacted 14
[m40] Nattokinase 4000 FU every other day 2026-01-11 - redacted 2
[m41] Iron 28 mg every other day 2026-01-11 - redacted 1
[m42] Acetyl-L-carnitine 1 g daily 2026-01-11 - redacted 6
[m43] Phosphatidylcholine 1 g as directed 2026-01-11 - redacted 5
[m44] L-Selenomethionine (Selenium) 100 mcg as directed 2026-01-11 - redacted 8
[m45] Zinc 15 mg as directed 2026-01-11 - redacted 16
[m46] Naltrexone (Low dose naltrexone) 3 mg daily 2026-01-11 - redacted 9
[m47] Ascorbic Acid (Vitamin C) 500 mg daily 2026-01-11 - redacted 8
[m48] Magnesium 300 mg as directed 2026-01-11 - redacted 15
[m49] Caprylic Acid 600 mg as directed 2026-01-11 - redacted 6
[m50] Quercetin Phytosome 250 mg as directed 2026-01-11 - redacted 8
[m51] Ezetimibe (Atozet) 10 mg daily 2026-01-11 - redacted 3
[m52] N-Acetylcysteine (NAC) 600 mg twice daily 2026-01-11 - redacted 8
[m53] Tocotrienols (Vitamin E) 150 mg as directed 2026-01-11 - redacted 9
[m54] Psyllium Husk 500 mg at bedtime 2026-01-11 - redacted 17
[m55] Cartigenix (Cartigenix) 1100 mg as directed 2026-01-11 - redacted 5
[m56] Cholecalciferol (Vitamin D3) 40 mcg as directed 2026-01-11 - redacted 9
[m57] Manganese 1 mg as directed 2026-01-11 - redacted 15
[m58] Cytidine Diphosphate Choline 250 mg twice daily 2026-01-11 - redacted 7
[m59] Lion's Mane Mushroom 500 mg twice daily 2026-01-11 - redacted 7
[m60] Magnolia Bark 400 mg every night 2026-01-11 - redacted 12
[m61] Lumbrokinase 20 mg as directed 2026-01-11 - redacted 2
[m62] Nicotinamide Riboside Chloride (Tru Niagen) 1000 mg as directed 2026-01-11 - redacted 5
[m63] Qualia Senolytic 0 as prescribed 2 days per month 2026-01-11 - redacted 17
[m64] Aged Garlic Extract (Kyolic) 1 g daily 2026-01-11 - redacted 4
[m65] Vitamin C 50 mg daily 2026-01-11 - redacted 1
[m7] Collagen 15 g daily 2026-01-11 - redacted 1
[m8] Betaine Anhydrous 1 g twice daily 2026-01-11 - redacted 7
[m9] Ashwagandha (Sensoril) 250 mg every evening 2026-01-11 - redacted 12

B. External Sources

Ref Title Accessed
[w10] The clinician’s guide to prevention and treatment of osteoporosis 2026-05-19
[w12] Reference ranges (“normal values”) for cardiac magnetic resonance (CMR) in adults and children: 2020 update 2026-05-19
[w13] Periodontitis | American Dental Association 2026-05-19
[w149] nih.gov 2026-05-25
[w14] AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management 2026-05-19
[w152] diyps.org 2026-05-25
[w156] oup.com 2026-05-25
[w163] nih.gov 2026-05-25
[w164] saedyn.es 2026-05-25
[w16] Current Criteria for the Diagnosis of Diabetes Mellitus: 2006 WHO Recommendations | Българско дружество по ендокринология 2026-05-19
[w172] researchgate.net 2026-05-25
[w173] nih.gov 2026-05-25
[w174] researchgate.net 2026-05-25
[w175] krmangalam.edu.in 2026-05-25
[w176] nbinno.com 2026-05-25
[w177] nih.gov 2026-05-25
[w178] droracle.ai 2026-05-25
[w179] mdpi.com 2026-05-25
[w17] Executive Summary - Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus - NCBI Bookshelf 2026-05-19
[w180] nih.gov 2026-05-25
[w181] encyclopedia.pub 2026-05-25
[w183] lolahealth.com 2026-05-25
[w184] nih.gov 2026-05-25
[w185] mhmedical.com 2026-05-25
[w186] viamedica.pl 2026-05-25
[w187] nih.gov 2026-05-25
[w188] nih.gov 2026-05-25
[w189] jnccn.org 2026-05-25
[w18] Recommended Tests for Identifying Prediabetes - NIDDK 2026-05-19
[w190] nih.gov 2026-05-25
[w191] rheumnow.com 2026-05-25
[w192] mui.ac.ir 2026-05-25
[w193] nih.gov 2026-05-25
[w194] researchgate.net 2026-05-25
[w195] nih.gov 2026-05-25
[w196] nih.gov 2026-05-25
[w19] Diabetes Diagnosis & Tests | ADA 2026-05-19
[w01] 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | JACC 2026-05-19
[w201] ciplamed.com 2026-05-25
[w203] kinnecttraining.com.au 2026-05-25
[w204] nih.gov 2026-05-25
[w209] drvoice.cn 2026-05-25
[w20] AJG-19-0314 165..178 2026-05-19
[w210] researchgate.net 2026-05-25
[w211] umn.edu 2026-05-27
[w214] nih.gov 2026-05-27
[w220] e-dmj.org 2026-05-27
[w224] mardenmedicalcentre.nhs.uk 2026-05-27
[w225] everydayhealth.com 2026-05-27
[w226] medscape.com 2026-05-27
[w229] healthbooktimes.org 2026-05-27
[w230] cornwall.nhs.uk 2026-05-27
[w24] AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part V: electrocardiogram changes associated with cardiac chamber hypertrophy: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology - PubMed 2026-05-19
[w25] Left atrial enlargement (Concept Id: C0238705) - MedGen - NCBI 2026-05-19
[w27] ICD Schema - ICD-API Homepage 2026-05-19
[w30] Laboratory diagnosis of primary immunodeficiencies - PubMed 2026-05-19
[w31] Immunodeficiency (Concept Id: C0021051) - MedGen - NCBI 2026-05-19
[w32] WHO-FIC Classifications 2026-05-19
[w33] AAN/ACR/IDSA 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease 2026-05-19
[w34] Restored CDC | Clinical Testing and Diagnosis for Schistosomiasis | Schistosomiasis | CDC 2026-05-19
[w35] MYCO - Overview: Mycoplasma pneumoniae Antibodies, IgG and IgM, Serum 2026-05-19
[w36] 096001: Coxsackie B Virus Antibodies | Labcorp 2026-05-19
[w37] Laboratory Testing for Chlamydia pneumoniae | C. pneumoniae | CDC 2026-05-19
[w38] Increased Frequency of Dysfunctional Siglec-7-CD57+PD-1+ Natural Killer Cells in Patients With Non-alcoholic Fatty Liver Disease - PubMed 2026-05-19
[w40] Further delineation of autosomal recessive intellectual disability syndrome caused by homozygous variant of the NSUN2 gene in a chinese pedigree - PubMed 2026-05-19
[w43] GeneReviews Glossary 2026-05-19
[w44] ACG-Genetic-Testing-Hereditary-GI-Cancer-Guideline-Summary.pdf 2026-05-19
[w45] AGA guidance: When to screen for pancreas cancer - American Gastroenterological Association 2026-05-19
[w47] A Prospective, Randomized Double-Blind, Placebo-Controlled Study of Safety and Efficacy of a High-Concentration Full-Spectrum Extract of Ashwagandha Root in Reducing Stress and Anxiety in Adults - PMC 2026-05-19
[w48] Late Night Salivary Cortisol in the diagnosis of neoplastic hypercortisolism (including cyclic Cushing's syndrome) - PubMed 2026-05-19
[w49] Primary Adrenal Insufficiency Guideline Resources | Endocrine Society 2026-05-19
[w04] Official Positions 2023 - Draft - ISCD 2026-05-19
[w50] Cross-reactivity of steroid hormone immunoassays: clinical significance and two-dimensional molecular similarity prediction | BMC Clinical Pathology | Springer Nature Link 2026-05-19
[w51] Effect of a proprietary Magnolia and Phellodendronextract on stress levels in healthy women: a pilot, double-blind, placebo-controlled clinical trial | Nutrition Journal | Springer Nature Link 2026-05-19
[w57] Late-night salivary cortisol measurement in the diagnosis of Cushing's syndrome | Nature Reviews Endocrinology 2026-05-19
[w58] The Functional and Clinical Significance of the 24-Hour Rhythm of Circulating Glucocorticoids - PubMed 2026-05-19
[w61] Rheumatoid Factor - StatPearls - NCBI Bookshelf 2026-05-19
[w62] Wilson's disease - Diagnosis and treatment - Mayo Clinic 2026-05-19
[w63] Copper - Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc - NCBI Bookshelf 2026-05-19
[w64] Background Information for Zinc - Interaction Profile for: Lead, Manganese, Zinc, and Copper - NCBI Bookshelf 2026-05-19
[w67] Methane on breath testing is associated with constipation: a systematic review and meta-analysis - PubMed 2026-05-19
[w06] ADAPTED FROM: 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy 2026-05-19
[w70] Lean, but not healthy: the 'metabolically obese, normal-weight' phenotype - PubMed 2026-05-19
[w72] Hypertensive Heart Disease - StatPearls - NCBI Bookshelf 2026-05-19
[w73] Association of Hepatic Steatosis With Subclinical Atherosclerosis: Systematic Review and Meta-Analysis - PubMed 2026-05-19
[w74] Dysregulated lipid metabolism links NAFLD to cardiovascular disease - PubMed 2026-05-19
[w75] Mechanisms of intrahepatic triglyceride accumulation - PubMed 2026-05-19
[w77] Hypergammaglobulinemia (Polyclonal Gammopathy) - StatPearls - NCBI Bookshelf 2026-05-19
[w79] Plasma levels of coagulation factors VIII and IX and risk of venous thromboembolism: Systematic review and meta-analysis - ScienceDirect 2026-05-19
[w07] 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines | JACC 2026-05-19
[w08] NGSP: HbA1c Assay Interferences 2026-05-19
[w09] ACR-Management-of-Incidental-Findings.pdf 2026-05-19
MEDICAL DISCLAIMER

This report is generated by an artificial intelligence system and is intended solely for informational and educational purposes. It does not constitute medical advice, diagnosis, or treatment. The analyses, interpretations, and recommendations contained herein are not a substitute for professional medical judgment. Always consult a qualified healthcare provider before making any decisions regarding your health, medications, or treatment plans. Individual health outcomes vary and AI-generated insights may not capture the full clinical picture. n1.care and its affiliates assume no liability for actions taken based on this report.

© 2026 n1.care · All rights reserved · Powered by AI-driven health intelligence
For clinical use by licensed practitioners only | n1.care